Next Article in Journal
Early Prediction of Breast Cancer Recurrence for Patients Treated with Neoadjuvant Chemotherapy: A Transfer Learning Approach on DCE-MRIs
Next Article in Special Issue
The Immune Microenvironment of Chordomas: An Immunohistochemical Analysis
Previous Article in Journal
Expression of NK Cell Receptor Ligands on Leukemic Cells Is Associated with the Outcome of Childhood Acute Leukemia
Previous Article in Special Issue
TLR4-Mediated Recognition of Mouse Polyomavirus Promotes Cancer-Associated Fibroblast-Like Phenotype and Cell Invasiveness
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 10
10.3390/cancers13102297
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer

by
Sonia Missiroli
1,
Mariasole Perrone
1,
Caterina Boncompagni
1,
Chiara Borghi
2,
Alberto Campagnaro
3,
Francesco Marchetti
3,
Gabriele Anania
3,
Pantaleo Greco
2,
Francesco Fiorica
4,
Paolo Pinton
1 and
Carlotta Giorgi
1,*
1
Department of Medical Sciences, Section of Experimental Medicine and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy
2
Department of Medical Sciences, Section of Obstetrics and Gynecology, University of Ferrara, 44121 Ferrara, Italy
3
Department of Medical Sciences, Section of General and Thoracic Surgery, University of Ferrara, 44121 Ferrara, Italy
4
Department of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, Ospedale Mater Salutis di Legnago, 37045 Verona, Italy
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(10), 2297; https://doi.org/10.3390/cancers13102297
Submission received: 30 March 2021 / Revised: 4 May 2021 / Accepted: 6 May 2021 / Published: 11 May 2021
(This article belongs to the Special Issue Inflammation and Tumor)
Browse Figures
Versions Notes

Abstract

:

Simple Summary

NLRP3 inflammasome is a cytoplasmic multiprotein complex that assembles in response to cellular distress and promotes maturation and release of the inflammatory cytokines interleukin-1β and IL-18, which contribute to immune responses and inflammation. Aberrant NLRP3 activation has divergent roles in the pathogenesis of inflammation-associated diseases such as cancer, as it can have both protumorigenic and antitumorigenic effects in a context-dependent and tissue-specific manner. Therefore, the fine-tuning of the NLRP3 inflammasome in cancer cells, through a wide range of agents including, such as inhibitors, antagonists and monoclonal antibodies, has been suggested as a viable approach to cancer therapy.

Abstract

Inflammasomes are multiprotein complexes that regulate the maturation and secretion of the proinflammatory cytokines interleukin-1beta (IL-1β and interleukin-18 (IL-18) in response to various intracellular stimuli. As a member of the inflammasomes family, NLRP3 is the most studied and best characterized inflammasome and has been shown to be involved in several pathologies. Recent findings have made it increasingly apparent that the NLRP3 inflammasome may also play a central role in tumorigenesis, and it has attracted attention as a potential anticancer therapy target. In this review, we discuss the role of NLRP3 in the development and progression of cancer, offering a detailed summary of NLRP3 inflammasome activation (and inhibition) in the pathogenesis of various forms of cancer. Moreover, we focus on the therapeutic potential of targeting NLRP3 for cancer therapy, emphasizing how understanding NLRP3 inflammasome-dependent cancer mechanisms might guide the development of new drugs that target the inflammatory response of tumor-associated cells.

1. Introduction

An association between inflammation and cancer development has long been appreciated, to the extent that the inflammatory response has been recognized to play a decisive role in the development and progression of cancer [1]. In the last decade, the term inflammasome was coined to describe a cytoplasmic multiprotein complex that recognizes signals of host cellular distress and activates proinflammatory caspases, which drive subsequent immune responses and inflammation [2]. Among the inflammasomes, NLRP3 is the most well studied and has been associated with the pathogenesis of multiple diseases, including neurodegenerative diseases (Alzheimer’s and Parkinson’s), atherosclerosis, hereditary cryopyrin-associated periodic syndromes (CAPSs), metabolic diseases and cancer [3]. Thus, considering the substantial role of NLRP3 in different inflammatory pathologies, it is not surprising that strategies targeting this inflammasome are hot topics of research. In this review, we will discuss the NLRP3 inflammasome as a double-edged sword in cancer, as it can have both protumorigenic and antitumorigenic effects not only in different cancers but also in a tissue-specific manner. Moreover, we will focus on current strategies for targeting the NLRP3 inflammasome, including a diverse range of agents, such as inhibitors, antagonists and monoclonal antibodies, which have potential for cancer treatment.

2. NLRP3 Inflammasome: Biology and Activation

The NLRP3 inflammasome is a critical component of the innate immune system and consists of NLRP3 (NLR family protein containing a pyrin domain 3), the adaptor apoptosis-associated speck-like protein (ASC, which contains a caspase activation and recruitment domain, CARD) and the effector pro-caspase 1. NLRP3 comprises three domains: An N-terminal pyrin domain (PYD), which interacts with the pyrin domain of ASC to initiate inflammasome assembly [4]; a central nucleotide-binding and oligomerization (NACHT) domain that is required for subsequent activation [5]; and a C-terminal leucine-rich repeat (LRR) domain, which has been recently demonstrated to be nonessential for NLRP3 inflammasome assembly [6]. ASC recruits and binds pro-caspase 1 via their shared domains, inducing autoproteolytic caspase-1 activation. Caspase-1 further induces the release of the inflammatory cytokines interleukin-1beta (IL-β) and interleukin-18 (IL-18) and cleaves gasdermin D (GSDMD), which in turn induces a form of programmed cell death known as pyroptosis [7,8].
Although a consensus for the precise localization of the NLRP3 inflammasome and its components has not yet been reached, several studies have indicated that, in resting conditions, NLRP3 resides in the endoplasmic reticulum (ER) and cytosol [9]. Upon activation, NLRP3 redistributes to mitochondria-associated membranes (MAMs) [10,11] and mitochondria [12]; however, one study proposed a strictly cytosolic localization of NLRP3 [13]. Although the NLRP3 inflammasome is the most studied and investigated, its activation mechanism remains unclear. To date, two steps have been proposed to underlie NLRP3 activation: priming and activation (Figure 1). The first step is triggered by the engagement of Toll-like receptors (TLRs) by their ligands or endogenous molecules, such as tumor necrosis factor (TNF) or IL-β, which leads to the transcription of NLRP3 and pro-IL-1β via the regulation of nuclear factor-kB (NF-κB) [14]. Moreover, recent studies have shown that the induction of NLRP3 expression during priming is also controlled by FAS-associated death domain protein (FADD) and caspase-8 [15].
In addition to control of NLRP3 activation via transcription, the priming step is also able to control inflammasome activation at the posttranscriptional level, as suggested by emerging evidence [16]. In particular, Schroder and colleagues demonstrated for the first time that priming of the NLRP3 inflammasome with short lipopolysaccharide (LPS) pretreatment could occur independently of NLRP3 protein expression induction [16].
It is well known that there are several NLRP3-activating stimuli and that they are heterogeneous; however, it is unclear why seemingly unrelated molecules can activate the same inflammasome. Given its heterogenous interaction partners, it is unlikely that NLRP3 physically interacts with its activators. All inflammasome activators induce cellular signaling that is sensed by the NLRP3 receptor. Numerous hypotheses for the origin of this signal have been proposed, including calcium (Ca2+) signaling, potassium (K+) efflux, effects of reactive oxygen species (ROS), lysosomal leakage, exposure to damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), and mitochondrial dysfunction [17,18].
Given that many stimuli, like nigericin, adenosine triphosphate (ATP) and particulates, lead to Ca2+ mobilization, different studies have suggested the involvement of Ca2+ signaling in NLRP3 inflammasome activation [19,20,21]. Ca2+ chelation using BAPTA-AM inhibits IL-1β release, but Ca2+ inhibition does not affect the activation of other inflammasomes, such as NLRC4 or AIM2 [19,22].
Several stresses trigger a change in the intracellular ionic composition that induces a conformational change in one of the inflammasome components, suggesting a role for K+ efflux in NLRP3 inflammasome activation [23,24]. Numerous studies agree that K+ efflux is a crucial event for inflammasome activation. Among these studies, Petrilli et al. demonstrated that in murine macrophages, NLRP3 inflammasome assembly occurs spontaneously at low K+ concentrations (below 90 mM) but is prevented at higher concentrations [24]. Many stimuli, including ATP and nigericin, act through a mechanism dependent on K+ efflux [25].
The involvement of mitochondrial dysfunction and ROS has been discussed for a long time, and ROS have been identified as important activators of the NLRP3 inflammasome [11,26]; in addition, several chemical inhibitors of ROS can prevent NLRP3 inflammasome activation [27,28]. Moreover, numerous stimuli inducing cell death and mitochondrial dysfunction promote mitochondrial DNA oxidation, which in turn activates inflammasomes [29].
In recent years, other cellular mechanisms have been proposed for inflammasome activation, such as chloride intracellular channel (CLIC)-dependent chloride (Cl-) efflux [30]. NLRP3 agonists induce K+ efflux, which causes mitochondrial damage and ROS production; in turn, mitochondrial ROS induce the translocation of CLICs to the plasma membrane for the induction of Cl- efflux to promote inflammasome assembly and IL-1β secretion [31].
In addition to canonical NLRP3 inflammasome activation, a noncanonical inflammasome activated by LPS-induced caspase-11 has also been discovered. Caspase-11 activated by LPS interacts with its substrate, the protein GSDMD, and thus mediates noncanonical inflammasome activation [7].
NLRP3 activation is regulated by different proteins, such as never in mitosis A (NIMA)-related kinase 7 (NEK7), guanylate-binding protein 5 (GBP5) and double-stranded RNA-dependent protein kinase (PKR, also known as EIF2AK2) [32,33,34]. Lu and colleagues demonstrated for the first time that PKR physically interacts with inflammasome components, including NLRP3, NLRP1, NLRC4, and AIM2, and broadly regulates inflammasome activation [32]. Although a recent study suggested that PKR modulates inflammation by regulating the expression of the NLRP3 inflammasome through the NF-κB pathway in periodontal diseases [35], further studies are required to clarify the role of PKR in NLRP3 inflammasome activation. GBP5 seems to have a similar behavior in inflammasome activation, promoting selective NLRP3 inflammasome responses to pathogenic live bacteria and soluble but not crystalline agents and double-stranded DNA [33]. However, the role of GBP5 needs further clarification.
Growing evidence has shown a key role for NEK7, one of the smallest members of the NRK family, which regulates mitotic progression and the DNA damage response. NEK7 consists of a core kinase domain and a short N-terminal tail. Although the kinase domains of NEK6 and NEK7 are notably conserved, with 87% sequence identity, it has been demonstrated that NEK6 cannot control NLRP3 inflammasome activation like NEK7 can, suggesting the specificity of the NEK7-NLRP3 interaction [36].
In support of the idea that NEK7 is a selective upstream regulator of NLRP3 inflammasome activation, it has been demonstrated that when NEK7 is absent, the activation of caspase-1 and IL-1β is abrogated after stimulation with NLRP3 inflammasome activators, while this phenomenon is not observed for the NLRC4 or AIM2 inflammasome [37].
Under resting conditions, NEK7 activity is low, but any disruption of homeostasis may be accompanied by the dysregulation of NEK7. Emerging evidence has revealed that NEK7 upregulation is caused by a subunit of NF-κB, p65. p65 binds to the NEK7 promoter region via effects of the LPS-induced TLR4/NF-κB pathway and upregulates NEK7 expression [38]. Several studies have investigated the interaction between NLRP3 and NEK7. Previous studies have revealed that both the NACHT and LRR domains of NLRP3 are involved in the interaction with NEK7. Further works suggested that the N-terminal region of the NEK7 catalytic domain mediates the NLRP3-NEK7 interaction [39].
However, despite being a widely studied area of research, many parts of this complex mechanism are unclear. Clearly understanding the specific mechanisms of NLRP3 inflammasome activation could help broaden the field of NLRP3 inflammasome regulation and provide more potential therapeutic targets.

3. Role of the NLRP3 Inflammasome in Cancer

In this section, we will provide a general overview of the involvement of the NLRP3 inflammasome in tumorigenesis (Table 1).

3.1. Role of NLRP3 in Tumors of the Gastrointestinal Tract

3.1.1. Colon Cancer

Colorectal cancer (CRC) is the third most common malignancy worldwide and has a high mortality rate due to its typical rapid progression with diagnosis at an advanced stage [99]. A Western diet, the aging of the world population and chronic inflammation are the main factors related to bowel inflammation and colitis-associated cancer (CAC). These factors lead to constant overproduction of pro-inflammatory cytokines such as IL-1β, IL-18, IL-6, TNF-α and DNA-damaging reactive oxygen and nitrogen species. All these molecules act as PAMPs and DAMPs that activate inflammasomes and promote intestinal epithelial cell proliferation, survival and angiogenesis, leading to epithelial dysplasia and invasive tumor formation [100].
The NLRP3 inflammasome and its activation in intestinal pathologies have been investigated predominantly in murine models of chemically induced intestinal inflammation. Such models feature epithelial barrier damage that is induced by invasion of gut microflora into the lamina propria and massive infiltration of inflammatory cells and upregulation of proinflammatory cytokines, which are features that are comparable to those seen in human ulcerative colitis [101]. However, the several studies that have been carried out in the last ten years depict a controversial role of NLRP3 in CRC, with some studies showing a protective role while others demonstrate a negative effect of NLRP3 activation.
The protective role of NLRP3 was suggested by experiments that showed that azoxymethane-dextran sodium sulfate (AOM-DSS) mice deficient in inflammasome components, including Nlrp3, Asc, Caspase-1, Caspase-11, IL-18 and IL-18r, were more susceptible to CRC than those without deficiencies and exhibited accelerated tumor growth accompanied by attenuated levels of IL-1β and IL-18 [40,41,42,43]. Moreover, NLRP3 inflammasome-derived IL-1β and IL-18 play a protective role against oxazolone-induced colitis [44], and a hyperactive NLRP3 inflammasome (such as that in the Nlrp3 R258W mutant mouse line) confers strong resistance to experimental colitis/CRC [45]. Intriguingly, the NLRP3 inflammasome suppresses CRC metastatic growth through IL-18 production by promoting hepatic natural killer (NK) cell tumoricidal activity [46]. In line with these published reports, Hu and colleagues reported data from a model in which caspase-1 deficiency enhanced inflammation-induced CRC formation through regulation of the epithelial cell response to injury; however, these effects were mediated through the NLRC4 inflammasome rather than through NLRP3 [47].
In contrast with these findings, another study reported that the NLRP3 inflammasome is a critical regulator of intestinal inflammation in the DSS colitis model [55], and Nlrp3-/- mice develop less severe colitis than wild-type mice and produce lower levels of pro-inflammatory cytokines in colonic tissue [55]. Interestingly, administration of the small molecule andrographolide (Andro), a natural compound, prevents tumorigenesis in a colitis-associated CRC model by inducing mitophagy, which results in NLRP3 inflammasome inhibition [102].
However, the inconsistent observations between these studies comparing wild-type mice and Nlrp3-/- mice may stem from methodological differences between the experimental models (DSS or AOM-DSS) as well as from differences in the composition of the intestinal flora of the mouse lines used.
A crucial study found that NLRP3 expression was upregulated in human CRC tissues compared to adjacent normal tissues and was associated with tumor invasion and poor prognosis [56]. The NLRP3 signaling pathway might correlate with the mTOR-S6K1-MAPK signaling pathway, which synergistically promotes the invasion and migration of CRC cells [103]. This notion was supported by a genetic study that reported an association between single nucleotide polymorphisms (SNPs) in the Nlrp3 gene and CRC patient survival, with NLRP3 SNPs contributing to an increase in IL-1β and subsequent IL-6 levels and a poor outcome [57]. Other studies determined that NLRP3 upregulation could contribute to CRC cell migration and invasion [58] via an inflammasome-independent mechanism [104].

3.1.2. Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive solid malignancies and has a devastating prognosis and limited therapeutic options. IL-1β is frequently upregulated in patients with pancreatic cancer (PC) and is associated with poor prognosis [62,63]. High NLRP3 signaling has been found in subsets of PDA-associated macrophages in both humans and mice, in which it promotes accelerated progression of PC [59]; moreover, increased NLRP3 expression correlates with proliferation and epithelial-mesenchymal transition (EMT)-induced cancer cell invasion [60]. Interestingly, the long noncoding RNA XLOC_000647 acts as a tumor suppressor and suppresses the progression of PC by downregulating NLRP3 [60].
IL-1β increases tumor infiltration of immunosuppressive macrophages and myeloid-derived suppressor cells (MDSCs), thereby promoting immune evasion, neoangiogenesis and tumor development [105]. IL-1β neutralization promotes intratumoral CD8+ T cell infiltration and function and sensitizes PDA to immunotherapy, confirming that the effects of tumor cell-derived IL-1β are NLRP3-dependent and identifying a tumor-supportive role for NLRP3 in PC [105]. In line with this notion, PC cell lines and tumor cell-conditioned macrophages are able to activate ASC and to induce the release of IL-1α and IL-1β which are crucial for the secretion of thymic stromal lymphoprotein (TSLP) by cancer-associated fibroblasts (CAFs), promoting Th2 inflammation [106] and increasing NF-kappaB activity and survival [107]. Treatment with anakinra, an IL-1R antagonist, in an orthotopic mouse model induced a reduction in TSLP expression with a downregulation of Th2 immunity, resulting in improved overall survival [106]. Intriguingly, the NLRP3 inflammasome can also control platelet activation, a key feature in PDA, by promoting platelet aggregation and cancer progression and interfering with patient survival [61]. Pharmacological inhibition of NLRP3 with MCC950 significantly inhibits platelet activation and aggregation and tumor progression [61].
Collectively, these data suggest that NLRP3 signaling accelerates the progression of pancreatic neoplasias and that targeting NLRP3 is a promising therapeutic strategy.

3.1.3. Gastric Cancer

Gastric cancer (GC) is a common malignancy in the digestive system. Most of the evidence regarding GC and the NLRP3 inflammasome is derived from studies involving Helicobacter pylori (H. pylori): gastric infection with H. pylori is one of the most relevant factors implicated in GC development. H. pylori appears to activate the NLRP3 inflammasome [108,109], leading to IL-1β and IL-18 secretion [110,111], which regulates gastric immunity. Following H. pylori infection, NLRP3 expression is dramatically enhanced, and IL-1β secretion by macrophages is increased [64]. MiR-22 acts as a suppressor of NLRP3 expression in both gastric epithelial cells and macrophages and attenuates H. pylori-induced gastric carcinogenesis [64]. The mucin MUC1, known for its functions as an epithelial barrier, protects against H. pylori-induced gastritis by inhibiting NLRP3 activation [112]. Therefore, elimination of H. pylori infection seems significant for preventing GC; by contrast, H. pylori seems to prevent the critical activation of NLRP3 in human immune cells [113].
In addition to H. pylori, Mycoplasma hyorhinis also induces IL-1β secretion in an NLRP3-dependent manner both in vitro and in vivo, and it appears capable of promoting GC cell migration and invasion depending on inflammasome activation [65]. Notably, IL-1β-mediated inflammation has been linked to gastric carcinogenesis [66,67,68], and polymorphisms in the IL-1β and IL-18 genes that lead to an increase in the levels of these pro-inflammatory factors increase the susceptibility to the development of GC [114,115,116,117].
In conclusion, NLRP3 seems to have a definite role in promoting gastric carcinogenesis, but its role in other gastrointestinal malignancies is still debated.

3.1.4. Hepatic Cancer

Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors worldwide. Studies that have directly assessed the intrinsic role of NLRP3 in the development and progression of HCC have depicted a complex scenario in which its role appears to be twofold.
The expression of all NLRP3 components is significantly downregulated in human HCC, and this deficiency correlates with advanced stage and poor pathological differentiation [48]. Moreover, 17b-estradiol (E2) and estrogen receptor beta (ERβ) protect against HCC by activating the NLRP3 inflammasome [118] and by triggering pyroptotic cell death and inhibiting protective autophagy [119,120]. Interestingly, NLRP3 is required for the suppression of CRC metastatic growth in the liver, and its tumor-suppressive function is mediated by IL-18 production, which acts on NK cells [46].
In sharp contrast with these notions, there are several studies that support protumoral activity of NLRP3 in the pathogenesis of HCC. Luteoloside, a natural flavonoid with several pharmacological activities, reduces intracellular ROS accumulation and thus suppresses NLRP3 inflammasome activation, limiting the proliferation and metastasis of HCC cells [121]. In line with this, the NLRP3 inflammasome pathway has been described to have a procarcinogenic effect in hep3B cells, in which tumor-suppressive miR-223 promotes apoptosis and inhibits the proliferation of HCC cells by negatively regulating NLRP3 and downstream cytokines [122]. Mice treated with diethylnitrosamine (DEN), a potent liver carcinogen, display elevated levels of NLRP3 and IL-1β, which have been associated with inflammatory conditions. Combination therapy with celastrol and metformin suppresses NLRP3 and IL-1β, enhances anti-inflammatory and antioxidant activities, and downregulates angiogenesis, metastasis and proliferation markers [123]. Similarly, anisonamide suppresses the growth of HCC and induces apoptosis by inhibiting NLRP3 expression and further inhibiting the activation of the NLRP3 inflammasome, thus reducing the production of IL-1β [124]. Recently, Brocker and colleagues provided evidence for a mechanism by which proliferator-activated receptor α (PPARα) suppresses hepatic inflammation during metabolic stress by targeting the lncRNA Gm15441 [125]. Gm15441 suppressed TXNIP and thus TXNIP-NLRP3 inflammasome activation, caspase-1 cleavage and the expression of IL-1β [125]. The authors speculate that Gm15441 is a plausible therapeutic target for the treatment of inflammatory disorders, potentially including HCC [125].
Taken together, these results unveil a dual role for the NLRP3 inflammasome in the pathogenesis of HCC, and additional studies are essential to deeply understand the relationship between HCC progression and the NLRP3 inflammasome.

3.2. Involvement of NLRP3 in Gynecological Cancers

3.2.1. Endometrial Carcinoma

Among gynecological cancers, endometrial carcinoma is the most common in developed countries, and its incidence is increasing [126]. Studies on inflammasome complexes have strengthened the correlations between estrogenic stimulation, inflammation and the development of endometrial neoplasia. Recently, the expression of NLRP3, its inflammasome components and ERβ was analyzed in endometrial cancer tissue samples from 31 patients [70]. Molecular analysis showed that estrogens enhanced the proliferation of endometrial cancer cells by upregulating NLRP3 expression via ERβ. On the other hand, knockdown of NLRP3 expression inhibited the growth of cancer cells and reduced caspase-1 activation and IL1β maturation. Therefore, the different roles of estrogen/ERβ/NLRP3 inflammasome activation may be related to estrogen levels and ERβ expression in endometrial cancer patients [70].
Moreover, Yang et al. confirmed the hyperexpression of NLRP3 and related proteins in endometrial cancer in an attempt to link them with the pyroptosis pathway [71].

3.2.2. Cervical Cancer

Cervical cancer is the second most common neoplasia in females worldwide. Its genesis is related to high-risk human papillomavirus (HR-HPV) infection [127]. However, HPV itself seems to be insufficient to induce the malignant transformation process. Chronic inflammation, along with HPV infection, is involved in carcinogenesis [128,129]. In 2016, Pontillo et al. investigated 12 SNPs in 7 inflammasome-related genes as possible risk factors for HPV infection susceptibility and/or progression to cervical cancer [72]. They found a statistically significant association between the Nlrp3 variant rs10754558 and HR-HPV resistance. Their results demonstrate that inflammasome genetics can affect HPV/host interactions in terms of virus susceptibility, virus persistence and cervical cancer progression [72]. Furthermore, the membrane glycoprotein CD200 of the immunoglobulin superfamily, and its soluble formulation CD200 fusion protein Fc (CD200Fc), has been demonstrated to play an active role in the suppression of the inflammatory activity of the TLR4-NF-kappaB and NLRP3 inflammasome pathways in LPS-induced cervical cancer cell lines [130].

3.2.3. Ovarian Cancer

Ovarian cancer is the third most common gynecological malignancy and has the highest mortality rate. Epithelial ovarian cancer (EOC) is the pathological subtype of more than 90% of cases [131].
Several factors including molecular pathway dysfunctions, such as deregulation of oxidoreductase activity, metabolism, hormone activity, the inflammatory response, the innate immune response, and cell–cell signaling have been involved in its pathogenesis. Only a few studies have so far investigated the role of NLRP3 in the pathogenesis of EOC. One study investigated the molecular mechanism involved in the malignant transformation of endometriosis nodules into clear cell and endometrioid EOC, analyzing a list of 18 genes related to the inflammasome complex, and indicated a role of inflammation/immunity in EOC transformation [73]. The study explored the correlation between these genes and patient survival, demonstrating a statistically significant correlation between high expression levels of NLRP3 and poor prognosis. These results suggest that inflammasome dysregulation could play a fundamental role in modulating malignant transformation of endometriosis and that NLRP3 signaling concomitant with persistent sterile inflammation could indicate the initial stage of ovarian carcinogenesis [73].
Luborsky et al. studied whether NLRP3 inflammasome components and their corresponding cytokine products were increased in ovarian tumors by analyzing chicken and human normal ovaries and ovarian tumors [132]. They found that the expression of caspase-1, IL-1β and IL-18 was higher in ovarian cancer tissues than in normal tissues; however, they found no difference in NLRP3 expression. The reasons why immune reactions may differ during the development and progression of ovarian tumors remain to be determined, but this study laid the foundation for future evaluation of the relationship between tumor initiation and early inflammatory events involved in ovarian cancer development [132]. Recently, the correlation between the survival of EOC patients and the expression levels of inflammasome components and their related genes has been investigated, emphasizing that high expression levels of NLRP3 are associated with poor patient prognosis [74].
All these results and some additional evidence [133] support the usage of NLRP3 inflammasome genes and their corresponding proteins as potential markers of EOC progression and prognosis and as potential therapeutic targets.

3.3. NLRP3 Inflammasome Involvement in Other Types of Cancer

The NLRP3 inflammasome complex has attracted considerable attention for its role in the development of several other cancer types, but this role remains unclear and controversial.

3.3.1. Lung Cancer

Lung cancer (LC) is a major cause of death in industrialized countries. The most frequent form is non-small-cell lung cancer (NSCLC), representing 85% of cases [134]. Several studies have established the link between chronic inflammation and LC, but they depict a setting in which the involvement of the NLRP3 inflammasome is controversial [135]. Alveolar macrophages (AMs), critical in local lung inflammation, from patients with LC show downregulation of NLRP3/caspase-1 inflammasome activation, which is characterized mainly by the impairment of IL-1β production [49]. Conversely, tumor-derived exosomal TRIM59 has been shown to rewire macrophages towards a protumoral pathway by degrading ABHD5 protein and exacerbating NLRP3 inflammasome activation, which promotes LC cell proliferation and invasion [75].
Overexpression of IL-1β in lung adenocarcinoma (ADC) cells results in the promotion of experimental lung metastasis via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules [76]. In line with this, NLRP3 promotes the mouse lung tumorigenesis induced by benzo(a)pyrene and LPS [77] and favors experimental lung metastasis development by affecting the ability of host NK cells to control the tumor [78]. Polydatin, a natural component, suppresses the proliferation and migration of NSCLC cells via the NF-κB pathway, inhibiting NLRP3 inflammasome activation [136,137]. In contrast, experimental metastasis is more pronounced in mice lacking IL-1β than in wild-type mice due to the increased number of regulatory T cells in mice lacking IL-1β, which favors the malignant process [138].
Interestingly, NLRP3 inflammasome elements were overexpressed in high-grade ADC, which is an NSCLC subtype, and in small-cell lung cancer (SCLC) [79], suggesting that they could be crucial biomarkers for LC as well as potential modulators of the biological behaviors of LC. Recently, the association between genetic variants in NLRP3 inflammasome genes and the survival of NSCLC patients has been assessed; two novel genetic variants (in BIRC3 and NRG1) have been associated with NSCLC and may affect patient survival [139].
Altogether, these data correlate the NLRP3 inflammasome with LC development; however, the exact molecular mechanisms linking the NLRP3 inflammasome to LC development are still unclear, and further investigation is needed.

3.3.2. Breast Cancer

Breast cancer (BC) is the leading cause of mortality in women, with BC accounting for 14–15% of all female cancer deaths worldwide [140].
Current studies underline the central role of the microenvironment and infiltrating immune cells in the migration and invasion of BC cells [141,142]. CAFs are an abundant population in the microenvironment of BC and take a center stage in tumorigenesis [143,144]. Recently, it has been proposed that CAFs sense DAMPs and thus activate the NLRP3 inflammasome pathway, leading to proinflammatory signaling and IL-1β release, which promote tumor progression and lung metastasis [144]. Targeting the NLRP3-IL-1β pathway activated by CAFs may be a beneficial approach for BC treatment. Accordingly, transcription factor EB (TFEB) modulates tumor-associated macrophage (TAM) gene expression in BC through several pathways, for example, by promoting NLRP3 inflammasome degradation [80]. Moreover, NLRP3 expression in tumor-infiltrating macrophages has been correlated with the survival, lymph node invasion and metastasis of mammary carcinoma patients [81]. Human BC tissues display unc-51-like autophagy activating kinase 1 (ULK1) deregulation that contributes to mitochondrial ROS accumulation and thus NLRP3 activation, which in turn promotes BC osteolytic bone metastasis [82].
In contrast with this view, Huang and colleagues demonstrated that NLRP3 activation is necessary to induce antitumor immunity in patients with BC [50]. Mechanistically, they identified that myeloid PTEN determines chemotherapy efficiency by activating the NLRP3 inflammasome, suggesting that manipulating the NLRP3-IL-1β axis might be able to overcome chemotherapy resistance in patients with tumors with PTEN loss [50].
The definitive functions of the NLRP3 inflammasome in mammary malignancy are still unknown, but several studies have demonstrated the pivotal function of IL-1β in tumorigenesis and neoplasm growth [145,146]. The inflammatory cytokine IL-1β positively regulates mammary tumor growth and invasiveness by affecting the nature of myeloid cells and promoting TAM differentiation [83]. In a transgenic mouse model, inducible fibroblast growth factor receptor 1 (iFGFR1) induces an increase in IL-1β that in turn regulates cyclooxygenase-2 expression, which promotes cell migration and favors mammary lesions [147].
Increased IL-1β levels in primary tissues and metastatic sites have been detected in a spontaneous murine mammary gland tumor model, suggesting that the IL-1β pathway promotes tumor growth and metastasis [84]. Significantly, IL-1R blockade with an antagonist reduces tumor growth and inhibits human BC progression [84].
Although further studies are needed, these data depict a clear protumoral role for NLRP3 in mammary cancer.

3.3.3. Head and Neck Squamous Cell Carcinoma

NLRP3 inflammasome activation has been demonstrated to promote inflammation-induced carcinogenesis in head and neck squamous cell carcinoma (HNSCC) [85], and P2 × 7R and NLRP3 have been found to be overexpressed in HNSCC in association with increased survival and invasiveness [86]. Additionally, the IL-1β concentration was increased in the peripheral blood of HNSCC patients [87]. In contrast, cluster of differentiation 38 (CD38) has been demonstrated to act as a tumor suppressor gene in HNSCC, triggering pyroptotic cell death by activating NLRP3 and caspase-1 [51]; thus, by inhibiting CD38 expression, HNSCC cells might be able to escape NLRP3 inflammasome-mediated pyroptosis [51].

3.3.4. Oral Cavity Squamous Cell Carcinoma

Interestingly, the levels of the NLRP3 complex components (NLRP3, ASC and IL-1β) were significantly elevated in oral cavity squamous cell carcinoma (OSCC) and contributed to tumor growth and metastasis [88,89]. High NLRP3 expression has been associated with a more malignant phenotype in OSCC and promotes 5-fluorouracil (5-FU) resistance [148]; therefore, targeting the ROS/NLRP3 inflammasome pathway may decrease the resistance of OSCC cells to 5-FU-based therapy [148]. As already demonstrated for gastric cancer, miR-22 suppresses growth, migration and invasion in OSCC cells by affecting the functions of the NLRP3 inflammasome [149]. Taken together, these data suggest that the NLRP3 inflammasome may be a potential target for OSCC therapy.

3.3.5. Skin Cancers

By performing a pancancer analysis of NLRP3 inflammasome-related genes across 24 human cancers, Ju M. and colleagues found that 15 cancers had significant differences in NLRP3 expression between normal and tumor samples [150]. Intriguingly, the researchers showed that highly malignant HCC and skin cutaneous melanoma (SKCM) were associated with low NLRP3 inflammasome scores, which could serve as independent prognostic factors in SKCM [150]. The mechanisms of the NLRP3 inflammasome in melanoma and other skin cancers are not clearly understood [151], but several reports have demonstrated the involvement of NLRP3 inflammasome components in tumorigenesis. Polymorphisms of NLRP3 are associated with the development of melanoma [90], and IL-1R-/- and caspase 1-/- mice rarely develop skin cancer after stimulation with chemical agents [91]. The NLRP3 inflammasome shows different levels of pathway activation according to disease stage: it is constitutively activated in late stages of melanoma, producing high levels of IL-1β in the microenvironment [152,153], while IL-1β secretion has been found to require the activation of the receptor IL-1R during intermediate stage cancer in vitro [153]. Moreover, Drexler et al. showed that infiltrating myeloid cells were mainly responsible for tumor-promoting IL-1β release in the tumor microenvironment [91]. Interestingly, the adaptor protein ASC also plays opposite roles in skin tumorigenesis, acting as a driver of tumorigenesis when expressed in infiltrating myeloid cells but as a tumor suppressor when expressed in keratinocytes [91].

3.3.6. Prostate Cancer

It is known that the microenvironment plays a pivotal role in both cancer development and progression [154]. IL-1β abundance in the tumor environment and its overexpression have already been associated with the progression of different cancer types [69], including prostate cancer (PCa) [93,155]. High levels of IL-1β and IL-18 have been found in the serum of patients with advanced PCa [92,156]. The proinflammatory cytokine IL-1β is overexpressed in an in vitro model of PCa, suggesting the activation of the NLRP3/caspase-1 pathway in malignant growth [93]. Cancer cell-derived extracellular vesicles (EVs) can modify the prostate microenvironment to promote cancer proliferation [157] and can promote the activation of the NLRP3 inflammasome and caspase-1 and IL-1β release, contributing to the maintenance of proinflammatory tumor conditions [93]. However, immunohistochemical experiments in human prostate samples demonstrated that there were no significant differences in NLRP3 expression between tumor and adjacent tissues, either benign or malignant, suggesting that NLRP3 might not be involved in PCa metastasis [158].

3.3.7. Gliomas

The role of the NLRP3 inflammasome and its components has also been extensively described in gliomas, a group of malignant neoplasms of the central nervous system, which led to the identification of a protumoral role for NLRP3 [159]. The upregulation of NLRP3 affects human glioma progression by activating the AKT signaling pathway [94] and IL-1β/NF-kappaB p65 signaling [160], thus promoting migration and invasion. In addition, glioma cells display aberrant expression of IL-1β, and NLRP3 seems to contribute to radiotherapy resistance [95]. Interestingly, beta-hydroxybutyrate has been recently reported to counteract cell migration by suppressing the activation of caspase-1 and the maturation of IL-1β [161].

3.3.8. Hematological Malignancies

To date, studies have addressed the role of NLRP3 in solid tumors, but this inflammasome has an important and still controversial role in hematological malignancies. It has been demonstrated that patients with primary lymphoma and acute myeloid leukemia (AML) display markedly increased expression of NLRP3 inflammasome molecules accompanied by overexpression of IL-18 mRNA [96,98]; nevertheless, chronic myeloid leukemia (CML) patients display lower levels of IL-1β or NLRP3 than controls [52]. Oncogenic KRAS leads to ROS production, NLRP3 activation and consecutive release of IL-1β in a myeloid leukemia mouse model, and KRAS-mutant human leukemia cells exhibit increased NLRP3 inflammasome activation [97]. Moreover, the activation of the NLRP3 inflammasome reduces the antitumor effects of dexamethasone in lymphoma, altering the c-myc/TP53 and bcl-2/bax equilibrium [98].
In contrast, the NLRP3 inflammasome seems to have antitumor activity in multiple myeloma (MM) [53] and chronic lymphocytic leukemia (CLL) [54], in which it is expressed at lower levels in cancer patients than in healthy controls. The downregulation of NLRP3 in CLL lymphocytes blocks cell proliferation and induces apoptosis, suggesting that the NLRP3 inflammasome works as a negative regulator of tumor growth [54].
Taken together, these data suggest that a unified mechanism for NLRP3 inflammasome activation and its involvement in cancer has not yet emerged, so future studies are needed to better clarify its role in each kind of tumor (Figure 2).

4. NLRP3 Inflammasome as a Promising Target for Cancer Therapy

The clinical relevance of the NLRP3 inflammasome in multiple forms of cancer highlights its therapeutic promise as a molecular target. Here, we list the several compounds that impinge on inflammasome activation or inhibit downstream products of inflammasome activation and that can affect cancer development (Table 2).
The first inhibitor of NLRP3 to be discovered was the sulfonylurea CP-456773/CRID3, recently named MCC950, a compound found to be a potent and specific small-molecule inhibitor of the NLRP3 pathway [162]. From a molecular point of view, MCC950 directly interacts with and affects the Walker B motif within the NLRP3 NACHT domain, thereby blocking ATP hydrolysis [163] and inducing NLRP3 to transition into an inactive conformation [164]. To date, MCC950 has been tested in more than 80 animal models of more than 50 diseases, and these studies triggered a major increase in the amount of NLRP3 research. In cancer treatment, MCC950 was found to suppress and delay tumor growth and reshape the antitumor response in an HNSCC mouse model by decreasing the number of immunosuppressive cells and improving T cell functions [87]; moreover, MCC950 was able to reduce cell proliferation in a panel of PC cells by inhibiting inflammation [165]. Notably, MCC950 reverses KRAS-driven cytopenia and myeloproliferation [97]. MCC950 was shown to be effective in inhibiting IL-1β secretion and activation of caspase-1 in murine ulcerative colitis [166]. Other compounds have been shown to be effective for the treatment of DSS-induced experimental colitis in mice. A novel tetrahydroquinoline inhibitor of NLRP3, compound 6, specifically inhibits NLRP3 activation in vivo and attenuates colitis severity in the DSS mouse model [167] by directly binding to the NACHT domain of NLRP3, inhibiting its ATPase activity and blocking ASC oligomerization [167]. 1-Ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole, a synthetic small molecular compound also named Fc11a-2, was shown to induce beneficial effects in the treatment of DSS-induced experimental colitis in mice by targeting the NLRP3 inflammasome and inhibiting cytokine release [168]. VI-16, a synthetic flavonoid compound, exerts potent anti-inflammatory effects on macrophages by inhibiting the binding of TXNIP to NLRP3 and thus reducing ROS production and inhibiting the NLRP3 inflammasome [169]. NF-kappaB signaling and consequent NLRP3 inflammasome activation have been shown to be suppressed by fraxinellone, a lactone compound [170], and by alpinetin, a novel plant flavonoid [171]; both alleviate DSS-induced colitis.
Recently, the omega class glutathione transferase (GSTO1-1) inhibitor C1-27 has been demonstrated to regulate the release of IL-1β and IL-18 by deglutathionylating NEK7 in the NLRP3 inflammasome [172] and thus to protect against CRC formation [173].
These studies provide evidence that NLRP3 inflammasome inhibitors can function as potential novel therapeutic agents for human inflammatory bowel disease and, considering the correlation between the NLRP3 inflammasome and cancer, suggest new avenues for CAC treatment.
Celastrol, a natural triterpene, has been demonstrated to be an important inhibitor of the NF-kappaB signaling pathway [174] and of the NLRP3 inflammasome, and suppressing caspase-1 activation and IL-1β secretion prevents DSS-induced colitis [175] and reduces the ability of macrophages to stimulate the migration and invasion of melanoma cells [152].
Oridonin specifically inhibits NLRP3 by forming a covalent bond with cysteine 279 of the NLRP3 NACHT domain to block the interaction with NEK7, thereby inhibiting NLRP3 inflammasome assembly [176]. Although there is no direct evidence that oridonin induces anticancer activity by inhibiting the NLRP3 inflammasome, its ability to suppress cell proliferation, migration and invasion has been described in ovarian [177], breast [179], osteosarcoma [178] and esophageal [180] cancers. The same idea may be applied to thalidomide, an efficient anti-inflammatory drug that is able to inhibit caspase-1 activation [181] and has antitumor activity in MM and PCa treatment [182,183].
Among small-molecule compounds with NLRP3 inhibitory activity, CY-09 increases gemcitabine sensitivity in triple-negative BC, limiting the activation of the EMT/IL-1β/Wnt/β-catenin signaling pathway [185]. CY-09 specifically binds the ATP-binding motif of NLRP3 and inhibits its ATPase activity [184].
The acetylase inhibitor SI-2, usually used as an antitumor reagent for anaplastic thyroid carcinoma 31977311, specifically inhibits NLRP3 inflammasome activation by disrupting the interaction between NLRP3 and ASC and by blocking ASC speck formation [186].
Despite the numerous molecules and drugs that have been shown to regulate inflammasome activity, the current treatments for NLRP3-related diseases in the clinic involve targeting IL-1β or IL-18. Canakinumab, a human anti-IL1β monoclonal antibody developed by Novartis, has evident antitumor effects against NSCLC [189,190] and is currently being tested in clinical trials for triple-negative BC, CRC, metastatic melanoma and PC treatment. Anakinra is a recombinant IL-1 receptor antagonist (IL-1RA), a well-known antioxidant and anti-inflammatory agent, that is able to block the signaling of both IL-1α and IL-1β through IL-1R [191]. Recently, anakinra has been demonstrated to mitigate glioblastoma aggressiveness by inhibiting the expression of proinflammatory cytokines and STAT3 [192], and as already mentioned, MCC950 is able to reverse KRAS-driven cytopenia and myeloproliferation [97]. Interestingly, anakinra significantly reduces the development and progression of BC bone metastasis [193]. Anakinra has been used in combination with other drugs in clinical trials: (i) with 5-FU and bevacizumab, in which it improved the survival rate and overall survival of patients affected by CRC [194]; (ii) with gemcitabine, nab-paclitaxel and cisplatin, in which it improved clinical outcomes in PDA (NCT02550327); and iii) with dexamethasone for treating patients with MM, in which it improved survival benefits. (NCT00635154).
Taken together, these findings highlight that directly targeting the NLRP3 inflammasome or its downstream pathways has begun to attract attention as a potential strategy for the development of novel anticancer therapies.

5. Concluding Remarks

Several biotech and pharmaceutical companies are now enthusiastically developing NLRP3 inhibitors that they think could address a wide variety of common diseases. Initially, most inhibitors of NLRP3 were developed to block the cytokines produced by its activation; at present, development strategies focus on compounds that directly bind to and perturb NLRP3 or target proteins that regulate posttranslational modification or degradation of inflammasome proteins. However, studies that have directly assessed the intrinsic role of NLRP3 in the regulation of cancer have depicted a complex scenario that mainly involves its aberrant expression or function. The seemingly contradictory function of inflammasome-dependent cytokines in tumor promotion and antitumor immunity is likely a result of the context-dependent and tissue-specific nature of such cytokines. Thus, to translate anti-NLRP3-based anticancer agents from the bench to the bedside, it will be important not only to identify molecules that selectively target NLRP3 or its downstream pathways in malignant cells but also to consider the metabolic heterogeneity of these malignant cells and the mechanisms through which such heterogeneity is connected to cancer.
In conclusion, alterations in NLRP3 inflammasome activation influence malignant transformation, tumor progression, and response to therapy by affecting an intricate network of cancer cell functions. Additional studies to disentangle the molecular and functional complexity of this network are urgently awaited.
Schematic representation of the several cancer types in which NLRP3 inflammasome is involved. Created with BioRender.com.

Author Contributions

S.M. and C.G. conceived the article; S.M., M.P., C.B. (Chiara Borghi), C.B. (Caterina Boncompagni), F.M. and A.C. wrote the manuscript with input from C.G., S.M. and P.P.; S.M. prepared display items (with https://biorender.com 30 March 2021) under supervision from C.G. The figures are original and have not been published before. S.M., C.G., G.A., P.P., F.F., and P.G. reviewed and edited the manuscript before submission. All authors addressed issued raised by reviewers and approved the submitted version of the article. All authors have read and agreed to the published version of the manuscript.

Funding

The Signal Transduction Laboratory is supported by the Italian Association for Cancer Research: Grant IG-23670 (to P.P.) and Grant IG-19803 (to C.G.); A-ROSE; the Italian Ministry of Health Grant (GR-2019-12369646 to S.M.), Progetti di Rilevante Interesse Nazionale (PRIN20177E9EPY to C.G. and PRIN2017E5L5P3 to P.P.) and local funds from the University of Ferrara.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

5-FU5-fluorouracil;
ADCadenocarcinoma;
AMLacute myeloid leukemia;
AOMazoxymethane;
ASCapoptosis-associated speck-like protein;
Androandrographolide;
ATPadenosine triphosphate;
BCbreast cancer;
Ca2+calcium ion;
CACcolitis-associated cancer;
CAFscancer associated fibroblasts
CAPSscryopyrin-associated periodic syndromes;
CARDcaspase activation and recruitment domain;
CLICschloride intracellular channels;
CLLchronic lymphocytic leukemia;
CMLchronic myeloid leukemia;
CRCcolorectal cancer;
DAMPsdamage-associated molecular patterns;
DENdiethylnitrosamine;
DSSdextran sodium sulphate;
EMTepithelial-mesenchymal transition;
EOCepithelial ovarian cancer;
ERendoplasmic reticulum;
ERβEstrogen Receptor β;
EVsextracellular vesicles;
FADDFAS-associated death domain protein;
GBP5guanylate-binding protein 5;
GCgastric cancer;
GSDMDgasdermin D;
GSTO1-1omega class glutathione transferase;
HCChepatocellular carcinoma;
HNSCChead and neck squamous cell carcinoma;
H. pyloriHelicobacter pylori;
HR-HPVhigh risk human papillomavirus
IL-βinterleukin-1beta;
IL-18interleukin-18;
IL-1RAIL-1 receptor antagonist;
K+potassium;
LClung cancer;
LRRleucine-rich repeat;
LPSlipopolysaccharide
MAMsmitochondria-associated membranes;
MDSCmyeloid-derived-suppressor cells;
MMmultiple myeloma;
NACHTnucleotide-binding and oligomerization;
NEK7never in mitosis A (NIMA)-related kinase 7;
NF-kappaBnuclear factor-kB
NKnatural killer;
NLRP3NLR family protein containing a pyrin domain 3;
NSCLCnon-small-cell lung cancer;
OSCCoral cavity squamous cell carcinoma;
PAMPspathogen-associated molecular patterns;
PCpancreatic cancer;
PCaprostate cancer;
PDApancreatic ductal adenocarcinoma;
PKRRNA-dependent protein kinase;
PPARαproliferator-activated receptor α;
PYDpyrin domain;
ROSreactive oxygen species;
SCLCsmall-cell lung cancer;
SNPssingle nucleotide polymorphisms;
SKCMskin cutaneous melanoma;
TAMstumor associated macrophages;
TFEBtranscription factor EB;
TLRstoll-like receptors;
TSLPthymic stromal lymphoprotein;
ULK1unc-51 like autophagy activating kinase 1.

References

  1. Zitvogel, L.; Kepp, O.; Galluzzi, L.; Kroemer, G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 2012, 13, 343–351. [Google Scholar] [CrossRef] [PubMed]
  2. Martinon, F.; Burns, K.; Tschopp, J. The Inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 2002, 10, 417–426. [Google Scholar] [CrossRef]
  3. Wang, Z.; Zhang, S.; Xiao, Y.; Zhang, W.; Wu, S.; Qin, T.; Yue, Y.; Qian, W.; Li, L. NLRP3 Inflammasome and Inflammatory Diseases. Oxid. Med. Cell. Longev. 2020, 2020, 4063562. [Google Scholar] [CrossRef] [PubMed]
  4. Guo, H.; Callaway, J.B.; Ting, J.P.Y. Inflammasomes: Mechanism of action, role in disease, and therapeutics. Nat. Med. 2015, 21, 677–687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Broz, P.; Dixit, V.M. Inflammasomes: Mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 2016, 16, 407–420. [Google Scholar] [CrossRef] [PubMed]
  6. Hafner-Bratkovič, I.; Sušjan, P.; Lainšček, D.; Tapia-Abellán, A.; Cerović, K.; Kadunc, L.; Angosto-Bazarra, D.; Pelegrin, P.; Jerala, R. NLRP3 lacking the leucine-rich repeat domain can be fully activated via the canonical inflammasome pathway. Nat. Commun. 2018, 9, 5182. [Google Scholar] [CrossRef] [Green Version]
  7. Kayagaki, N.; Stowe, I.B.; Lee, B.L.; O’Rourke, K.; Anderson, K.; Warming, S.; Cuellar, T.L.; Haley, B.; Roose-Girma, M.; Phung, Q.T.; et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 2015, 526, 666–671. [Google Scholar] [CrossRef]
  8. SShi, J.; Zhao, Y.; Wang, K.; Shi, X.; Wang, Y.; Huang, H.; Zhuang, Y.; Cai, T.; Wang, F.; Shao, F. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 2015, 526, 660–665. [Google Scholar] [CrossRef]
  9. Hamilton, C.; Anand, P.K. Right place, right time: Localisation and assembly of the NLRP3 inflammasome. F1000Research 2019, 8. [Google Scholar] [CrossRef] [Green Version]
  10. Missiroli, S.; Patergnani, S.; Caroccia, N.; Pedriali, G.; Perrone, M.; Previati, M.; Wieckowski, M.R.; Giorgi, C. Mitochondria-associated membranes (MAMs) and inflammation. Cell Death Dis. 2018, 9, 329. [Google Scholar] [CrossRef] [Green Version]
  11. Zhou, R.; Yazdi, A.S.; Menu, P.; Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469, 221–225. [Google Scholar] [CrossRef]
  12. Yang, C.S.; Kim, J.J.; Kim, T.S.; Lee, P.Y.; Kim, S.Y.; Lee, H.M.; Shin, D.M.; Nguyen, L.T.; Lee, M.S.; Jin, H.S.; et al. Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome. Nat. Commun. 2015, 6, 6115. [Google Scholar] [CrossRef] [Green Version]
  13. Wang, Y.; Yang, C.; Mao, K.; Chen, S.; Meng, G.; Sun, B. Cellular localization of NLRP3 inflammasome. Protein Cell 2013, 4, 425–431. [Google Scholar] [CrossRef] [Green Version]
  14. Bauernfeind, F.G.; Horvath, G.; Stutz, A.; Alnemri, E.S.; MacDonald, K.; Speert, D.; Fernandes-Alnemri, T.; Wu, J.; Monks, B.G.; Fitzgerald, K.A.; et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 2009, 183, 787–791. [Google Scholar] [CrossRef]
  15. Gurung, P.; Anand, P.K.; Malireddi, R.K.; Vande Walle, L.; Van Opdenbosch, N.; Dillon, C.P.; Weinlich, R.; Green, D.R.; Lamkanfi, M.; Kanneganti, T.D. FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. J. Immunol. 2014, 192, 1835–1846. [Google Scholar] [CrossRef] [Green Version]
  16. Schroder, K.; Sagulenko, V.; Zamoshnikova, A.; Richards, A.A.; Cridland, J.A.; Irvine, K.M.; Stacey, K.J.; Sweet, M.J. Acute lipopolysaccharide priming boosts inflammasome activation independently of inflammasome sensor induction. Immunobiology 2012, 217, 1325–1329. [Google Scholar] [CrossRef] [Green Version]
  17. Kelley, N.; Jeltema, D.; Duan, Y.; He, Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int. J. Mol. Sci. 2019, 20, 3328. [Google Scholar] [CrossRef] [Green Version]
  18. Giorgi, C.; Danese, A.; Missiroli, S.; Patergnani, S.; Pinton, P. Calcium Dynamics as a Machine for Decoding Signals. Trends Cell Biol. 2018, 28, 258–273. [Google Scholar] [CrossRef]
  19. Murakami, T.; Ockinger, J.; Yu, J.; Byles, V.; McColl, A.; Hofer, A.M.; Horng, T. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl. Acad. Sci. USA 2012, 109, 11282–11287. [Google Scholar] [CrossRef] [Green Version]
  20. Rossol, M.; Pierer, M.; Raulien, N.; Quandt, D.; Meusch, U.; Rothe, K.; Schubert, K.; Schoneberg, T.; Schaefer, M.; Krugel, U.; et al. Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nat. Commun. 2012, 3, 1329. [Google Scholar] [CrossRef] [Green Version]
  21. Giorgi, C.; Marchi, S.; Pinton, P. The machineries, regulation and cellular functions of mitochondrial calcium. Nat. Rev. Mol. Cell Biol. 2018, 19, 713–730. [Google Scholar] [CrossRef]
  22. Lee, G.S.; Subramanian, N.; Kim, A.I.; Aksentijevich, I.; Goldbach-Mansky, R.; Sacks, D.B.; Germain, R.N.; Kastner, D.L.; Chae, J.J. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 2012, 492, 123–127. [Google Scholar] [CrossRef] [Green Version]
  23. Munoz-Planillo, R.; Kuffa, P.; Martinez-Colon, G.; Smith, B.L.; Rajendiran, T.M.; Nunez, G. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013, 38, 1142–1153. [Google Scholar] [CrossRef] [Green Version]
  24. Petrilli, V.; Papin, S.; Dostert, C.; Mayor, A.; Martinon, F.; Tschopp, J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 2007, 14, 1583–1589. [Google Scholar] [CrossRef] [PubMed]
  25. Mariathasan, S.; Weiss, D.S.; Newton, K.; McBride, J.; O’Rourke, K.; Roose-Girma, M.; Lee, W.P.; Weinrauch, Y.; Monack, D.M.; Dixit, V.M. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006, 440, 228–232. [Google Scholar] [CrossRef] [PubMed]
  26. Nakahira, K.; Haspel, J.A.; Rathinam, V.A.; Lee, S.J.; Dolinay, T.; Lam, H.C.; Englert, J.A.; Rabinovitch, M.; Cernadas, M.; Kim, H.P.; et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 2011, 12, 222–230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Elliott, E.I.; Sutterwala, F.S. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol. Rev. 2015, 265, 35–52. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Lawlor, K.E.; Vince, J.E. Ambiguities in NLRP3 inflammasome regulation: Is there a role for mitochondria? Biochim. Biophys. Acta 2014, 1840, 1433–1440. [Google Scholar] [CrossRef] [PubMed]
  29. Shimada, K.; Crother, T.R.; Karlin, J.; Dagvadorj, J.; Chiba, N.; Chen, S.; Ramanujan, V.K.; Wolf, A.J.; Vergnes, L.; Ojcius, D.M.; et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012, 36, 401–414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Domingo-Fernandez, R.; Coll, R.C.; Kearney, J.; Breit, S.; O’Neill, L.A.J. The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1beta transcription and activate the NLRP3 inflammasome. J. Biol. Chem. 2017, 292, 12077–12087. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Tang, T.; Lang, X.; Xu, C.; Wang, X.; Gong, T.; Yang, Y.; Cui, J.; Bai, L.; Wang, J.; Jiang, W.; et al. CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Nat. Commun. 2017, 8, 202. [Google Scholar] [CrossRef]
  32. Lu, B.; Nakamura, T.; Inouye, K.; Li, J.; Tang, Y.; Lundback, P.; Valdes-Ferrer, S.I.; Olofsson, P.S.; Kalb, T.; Roth, J.; et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012, 488, 670–674. [Google Scholar] [CrossRef] [Green Version]
  33. Shenoy, A.R.; Wellington, D.A.; Kumar, P.; Kassa, H.; Booth, C.J.; Cresswell, P.; MacMicking, J.D. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science 2012, 336, 481–485. [Google Scholar] [CrossRef]
  34. Zhao, N.; Li, C.C.; Di, B.; Xu, L.L. Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors. J. Autoimmun. 2020, 113, 102515. [Google Scholar] [CrossRef]
  35. Yoshida, K.; Okamura, H.; Hiroshima, Y.; Abe, K.; Kido, J.I.; Shinohara, Y.; Ozaki, K. PKR induces the expression of NLRP3 by regulating the NF-kappaB pathway in Porphyromonas gingivalis-infected osteoblasts. Exp. Cell Res. 2017, 354, 57–64. [Google Scholar] [CrossRef]
  36. Feige, E.; Motro, B. The related murine kinases, Nek6 and Nek7, display distinct patterns of expression. Mech. Dev. 2002, 110, 219–223. [Google Scholar] [CrossRef]
  37. He, Y.; Zeng, M.Y.; Yang, D.; Motro, B.; Nunez, G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 2016, 530, 354–357. [Google Scholar] [CrossRef] [Green Version]
  38. Chen, X.; Liu, G.; Yuan, Y.; Wu, G.; Wang, S.; Yuan, L. NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-kappaB signaling. Cell Death Dis. 2019, 10, 906. [Google Scholar] [CrossRef] [PubMed]
  39. Richards, M.W.; O’Regan, L.; Mas-Droux, C.; Blot, J.M.; Cheung, J.; Hoelder, S.; Fry, A.M.; Bayliss, R. An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7 kinase is released through binding of Nek9. Mol. Cell 2009, 36, 560–570. [Google Scholar] [CrossRef] [PubMed]
  40. Allen, I.C.; TeKippe, E.M.; Woodford, R.M.; Uronis, J.M.; Holl, E.K.; Rogers, A.B.; Herfarth, H.H.; Jobin, C.; Ting, J.P. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 2010, 207, 1045–1056. [Google Scholar] [CrossRef]
  41. Hirota, S.A.; Ng, J.; Lueng, A.; Khajah, M.; Parhar, K.; Li, Y.; Lam, V.; Potentier, M.S.; Ng, K.; Bawa, M.; et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm. Bowel Dis. 2011, 17, 1359–1372. [Google Scholar] [CrossRef] [PubMed]
  42. Zaki, M.H.; Boyd, K.L.; Vogel, P.; Kastan, M.B.; Lamkanfi, M.; Kanneganti, T.D. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32, 379–391. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Zaki, M.H.; Vogel, P.; Body-Malapel, M.; Lamkanfi, M.; Kanneganti, T.D. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J. Immunol. 2010, 185, 4912–4920. [Google Scholar] [CrossRef] [Green Version]
  44. Itani, S.; Watanabe, T.; Nadatani, Y.; Sugimura, N.; Shimada, S.; Takeda, S.; Otani, K.; Hosomi, S.; Nagami, Y.; Tanaka, F.; et al. NLRP3 inflammasome has a protective effect against oxazolone-induced colitis: A possible role in ulcerative colitis. Sci. Rep. 2016, 6, 39075. [Google Scholar] [CrossRef]
  45. Yao, X.; Zhang, C.; Xing, Y.; Xue, G.; Zhang, Q.; Pan, F.; Wu, G.; Hu, Y.; Guo, Q.; Lu, A.; et al. Remodelling of the gut microbiota by hyperactive NLRP3 induces regulatory T cells to maintain homeostasis. Nat. Commun. 2017, 8, 1896. [Google Scholar] [CrossRef] [Green Version]
  46. Dupaul-Chicoine, J.; Arabzadeh, A.; Dagenais, M.; Douglas, T.; Champagne, C.; Morizot, A.; Rodrigue-Gervais, I.G.; Breton, V.; Colpitts, S.L.; Beauchemin, N.; et al. The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity. Immunity 2015, 43, 751–763. [Google Scholar] [CrossRef] [Green Version]
  47. Hu, B.; Elinav, E.; Huber, S.; Booth, C.J.; Strowig, T.; Jin, C.; Eisenbarth, S.C.; Flavell, R.A. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl. Acad. Sci. USA 2010, 107, 21635–21640. [Google Scholar] [CrossRef] [Green Version]
  48. Wei, Q.; Mu, K.; Li, T.; Zhang, Y.; Yang, Z.; Jia, X.; Zhao, W.; Huai, W.; Guo, P.; Han, L. Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. Lab. Investig. 2014, 94, 52–62. [Google Scholar] [CrossRef] [Green Version]
  49. Lasithiotaki, I.; Tsitoura, E.; Samara, K.D.; Trachalaki, A.; Charalambous, I.; Tzanakis, N.; Antoniou, K.M. NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer. PLoS ONE 2018, 13, e0205242. [Google Scholar] [CrossRef] [Green Version]
  50. Huang, Y.; Wang, H.; Hao, Y.; Lin, H.; Dong, M.; Ye, J.; Song, L.; Wang, Y.; Li, Q.; Shan, B.; et al. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. Nat. Cell Biol. 2020, 22, 716–727. [Google Scholar] [CrossRef]
  51. Zhang, M.J.; Gao, W.; Liu, S.; Siu, S.P.; Yin, M.; Ng, J.C.; Chow, V.L.; Chan, J.Y.; Wong, T.S. CD38 triggers inflammasome-mediated pyroptotic cell death in head and neck squamous cell carcinoma. Am. J. Cancer Res. 2020, 10, 2895–2908. [Google Scholar]
  52. Zhang, A.; Yu, J.; Yan, S.; Zhao, X.; Chen, C.; Zhou, Y.; Zhao, X.; Hua, M.; Wang, R.; Zhang, C.; et al. The genetic polymorphism and expression profiles of NLRP3 inflammasome in patients with chronic myeloid leukemia. Hum. Immunol. 2018, 79, 57–62. [Google Scholar] [CrossRef]
  53. Li, Y.; Li, N.; Yan, Z.; Li, H.; Chen, L.; Zhang, Z.; Fan, G.; Xu, K.; Li, Z. Dysregulation of the NLRP3 inflammasome complex and related cytokines in patients with multiple myeloma. Hematology 2016, 21, 144–151. [Google Scholar] [CrossRef]
  54. Salaro, E.; Rambaldi, A.; Falzoni, S.; Amoroso, F.S.; Franceschini, A.; Sarti, A.C.; Bonora, M.; Cavazzini, F.; Rigolin, G.M.; Ciccone, M.; et al. Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death. Sci. Rep. 2016, 6, 26280. [Google Scholar] [CrossRef] [Green Version]
  55. Bauer, C.; Duewell, P.; Mayer, C.; Lehr, H.A.; Fitzgerald, K.A.; Dauer, M.; Tschopp, J.; Endres, S.; Latz, E.; Schnurr, M. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010, 59, 1192–1199. [Google Scholar] [CrossRef] [Green Version]
  56. Wang, B.; Li, H.; Wang, X.; Zhu, X. The association of aberrant expression of NLRP3 and p-S6K1 in colorectal cancer. Pathol. Res. Pract. 2020, 216, 152737. [Google Scholar] [CrossRef]
  57. Ungerback, J.; Belenki, D.; Jawad ul-Hassan, A.; Fredrikson, M.; Fransen, K.; Elander, N.; Verma, D.; Soderkvist, P. Genetic variation and alterations of genes involved in NFkappaB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis 2012, 33, 2126–2134. [Google Scholar] [CrossRef] [Green Version]
  58. Deng, Q.; Geng, Y.; Zhao, L.; Li, R.; Zhang, Z.; Li, K.; Liang, R.; Shao, X.; Huang, M.; Zuo, D.; et al. NLRP3 inflammasomes in macrophages drive colorectal cancer metastasis to the liver. Cancer Lett. 2019, 442, 21–30. [Google Scholar] [CrossRef]
  59. Daley, D.; Mani, V.R.; Mohan, N.; Akkad, N.; Pandian, G.; Savadkar, S.; Lee, K.B.; Torres-Hernandez, A.; Aykut, B.; Diskin, B.; et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J. Exp. Med. 2017, 214, 1711–1724. [Google Scholar] [CrossRef] [Green Version]
  60. Hu, H.; Wang, Y.; Ding, X.; He, Y.; Lu, Z.; Wu, P.; Tian, L.; Yuan, H.; Liu, D.; Shi, G.; et al. Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regulating NLRP3. Mol. Cancer 2018, 17, 18. [Google Scholar] [CrossRef] [Green Version]
  61. Boone, B.A.; Murthy, P.; Miller-Ocuin, J.L.; Liang, X.; Russell, K.L.; Loughran, P.; Gawaz, M.; Lotze, M.T.; Zeh, H.J., 3rd; Vogel, S. The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth. Ann. Hematol. 2019, 98, 1603–1610. [Google Scholar] [CrossRef] [PubMed]
  62. Maker, A.V.; Katabi, N.; Qin, L.X.; Klimstra, D.S.; Schattner, M.; Brennan, M.F.; Jarnagin, W.R.; Allen, P.J. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin. Cancer Res. 2011, 17, 1502–1508. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Mitsunaga, S.; Ikeda, M.; Shimizu, S.; Ohno, I.; Furuse, J.; Inagaki, M.; Higashi, S.; Kato, H.; Terao, K.; Ochiai, A. Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 2013, 108, 2063–2069. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Li, S.; Liang, X.; Ma, L.; Shen, L.; Li, T.; Zheng, L.; Sun, A.; Shang, W.; Chen, C.; Zhao, W.; et al. MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis. Oncogene 2018, 37, 884–896. [Google Scholar] [CrossRef]
  65. Xu, Y.; Li, H.; Chen, W.; Yao, X.; Xing, Y.; Wang, X.; Zhong, J.; Meng, G. Mycoplasma hyorhinis activates the NLRP3 inflammasome and promotes migration and invasion of gastric cancer cells. PLoS ONE 2013, 8, e77955. [Google Scholar] [CrossRef] [Green Version]
  66. Mitchell, P.J.; Afzali, B.; Fazekasova, H.; Chen, D.; Ali, N.; Powell, N.; Lord, G.M.; Lechler, R.I.; Lombardi, G. Helicobacter pylori induces in-vivo expansion of human regulatory T cells through stimulating interleukin-1beta production by dendritic cells. Clin. Exp. Immunol. 2012, 170, 300–309. [Google Scholar] [CrossRef] [Green Version]
  67. Resende, C.; Regalo, G.; Duraes, C.; Pinto, M.T.; Wen, X.; Figueiredo, C.; Carneiro, F.; Machado, J.C. Interleukin-1B signalling leads to increased survival of gastric carcinoma cells through a CREB-C/EBPbeta-associated mechanism. Gastric Cancer 2016, 19, 74–84. [Google Scholar] [CrossRef] [Green Version]
  68. Shigematsu, Y.; Niwa, T.; Rehnberg, E.; Toyoda, T.; Yoshida, S.; Mori, A.; Wakabayashi, M.; Iwakura, Y.; Ichinose, M.; Kim, Y.J.; et al. Interleukin-1beta induced by Helicobacter pylori infection enhances mouse gastric carcinogenesis. Cancer Lett. 2013, 340, 141–147. [Google Scholar] [CrossRef]
  69. Apte, R.N.; Dotan, S.; Elkabets, M.; White, M.R.; Reich, E.; Carmi, Y.; Song, X.; Dvozkin, T.; Krelin, Y.; Voronov, E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006, 25, 387–408. [Google Scholar] [CrossRef]
  70. Liu, S.G.; Wu, X.X.; Hua, T.; Xin, X.Y.; Feng, D.L.; Chi, S.Q.; Wang, X.X.; Wang, H.B. NLRP3 inflammasome activation by estrogen promotes the progression of human endometrial cancer. OncoTargets Ther. 2019, 12, 6927–6936. [Google Scholar] [CrossRef] [Green Version]
  71. Yang, Y.; Liu, P.Y.; Bao, W.; Chen, S.J.; Wu, F.S.; Zhu, P.Y. Hydrogen inhibits endometrial cancer growth via a ROS/NLRP3/caspase-1/GSDMD-mediated pyroptotic pathway. BMC Cancer 2020, 20, 28. [Google Scholar] [CrossRef]
  72. Pontillo, A.; Bricher, P.; Leal, V.N.; Lima, S.; Souza, P.R.; Crovella, S. Role of inflammasome genetics in susceptibility to HPV infection and cervical cancer development. J. Med. Virol. 2016, 88, 1646–1651. [Google Scholar] [CrossRef]
  73. Chang, C.M.; Wang, M.L.; Lu, K.H.; Yang, Y.P.; Juang, C.M.; Wang, P.H.; Hsu, R.J.; Yu, M.H.; Chang, C.C. Integrating the dysregulated inflammasome-based molecular functionome in the malignant transformation of endometriosis-associated ovarian carcinoma. Oncotarget 2018, 9, 3704–3726. [Google Scholar] [CrossRef] [Green Version]
  74. Su, K.M.; Wang, P.H.; Yu, M.H.; Chang, C.M.; Chang, C.C. The recent progress and therapy in endometriosis-associated ovarian cancer. J. Chin. Med. Assoc. 2020, 83, 227–232. [Google Scholar] [CrossRef]
  75. Liang, M.; Chen, X.; Wang, L.; Qin, L.; Wang, H.; Sun, Z.; Zhao, W.; Geng, B. Cancer-derived exosomal TRIM59 regulates macrophage NLRP3 inflammasome activation to promote lung cancer progression. J. Exp. Clin. Cancer Res. 2020, 39, 176. [Google Scholar] [CrossRef]
  76. Yano, S.; Nokihara, H.; Yamamoto, A.; Goto, H.; Ogawa, H.; Kanematsu, T.; Miki, T.; Uehara, H.; Saijo, Y.; Nukiwa, T.; et al. Multifunctional interleukin-1beta promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules. Cancer Sci. 2003, 94, 244–252. [Google Scholar] [CrossRef] [Green Version]
  77. Huang, L.; Duan, S.; Shao, H.; Zhang, A.; Chen, S.; Zhang, P.; Wang, N.; Wang, W.; Wu, Y.; Wang, J.; et al. NLRP3 deletion inhibits inflammation-driven mouse lung tumorigenesis induced by benzo(a)pyrene and lipopolysaccharide. Respir. Res. 2019, 20, 20. [Google Scholar] [CrossRef]
  78. Chow, M.T.; Sceneay, J.; Paget, C.; Wong, C.S.; Duret, H.; Tschopp, J.; Moller, A.; Smyth, M.J. NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res. 2012, 72, 5721–5732. [Google Scholar] [CrossRef] [Green Version]
  79. Kong, H.; Wang, Y.; Zeng, X.; Wang, Z.; Wang, H.; Xie, W. Differential expression of inflammasomes in lung cancer cell lines and tissues. Tumour. Biol. 2015, 36, 7501–7513. [Google Scholar] [CrossRef]
  80. Li, Y.; Hodge, J.; Liu, Q.; Wang, J.; Wang, Y.; Evans, T.D.; Altomare, D.; Yao, Y.; Murphy, E.A.; Razani, B.; et al. TFEB is a master regulator of tumor-associated macrophages in breast cancer. J. Immunother. Cancer 2020, 8. [Google Scholar] [CrossRef]
  81. Weichand, B.; Popp, R.; Dziumbla, S.; Mora, J.; Strack, E.; Elwakeel, E.; Frank, A.C.; Scholich, K.; Pierre, S.; Syed, S.N.; et al. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1beta. J. Exp. Med. 2017, 214, 2695–2713. [Google Scholar] [CrossRef] [PubMed]
  82. Deng, R.; Zhang, H.L.; Huang, J.H.; Cai, R.Z.; Wang, Y.; Chen, Y.H.; Hu, B.X.; Ye, Z.P.; Li, Z.L.; Mai, J.; et al. MAPK1/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis. Autophagy 2020, 1–19. [Google Scholar] [CrossRef] [PubMed]
  83. Kaplanov, I.; Carmi, Y.; Kornetsky, R.; Shemesh, A.; Shurin, G.V.; Shurin, M.R.; Dinarello, C.A.; Voronov, E.; Apte, R.N. Blocking IL-1beta reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc. Natl. Acad. Sci. USA 2019, 116, 1361–1369. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Guo, B.; Fu, S.; Zhang, J.; Liu, B.; Li, Z. Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci. Rep. 2016, 6, 36107. [Google Scholar] [CrossRef]
  85. Huang, C.F.; Chen, L.; Li, Y.C.; Wu, L.; Yu, G.T.; Zhang, W.F.; Sun, Z.J. NLRP3 inflammasome activation promotes inflammation-induced carcinogenesis in head and neck squamous cell carcinoma. J. Exp. Clin. Cancer Res. 2017, 36, 116. [Google Scholar] [CrossRef]
  86. Bae, J.Y.; Lee, S.W.; Shin, Y.H.; Lee, J.H.; Jahng, J.W.; Park, K. P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer. Oncotarget 2017, 8, 48972–48982. [Google Scholar] [CrossRef] [Green Version]
  87. Chen, L.; Huang, C.F.; Li, Y.C.; Deng, W.W.; Mao, L.; Wu, L.; Zhang, W.F.; Zhang, L.; Sun, Z.J. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma. Cell. Mol. Life Sci. 2018, 75, 2045–2058. [Google Scholar] [CrossRef]
  88. Wang, H.; Luo, Q.; Feng, X.; Zhang, R.; Li, J.; Chen, F. NLRP3 promotes tumor growth and metastasis in human oral squamous cell carcinoma. BMC Cancer 2018, 18, 500. [Google Scholar] [CrossRef] [Green Version]
  89. Wu, C.S.; Chang, K.P.; OuYang, C.N.; Kao, H.K.; Hsueh, C.; Chen, L.C.; Cheng, H.Y.; Liang, Y.; Liou, W.; Liang, C.L.; et al. ASC contributes to metastasis of oral cavity squamous cell carcinoma. Oncotarget 2016, 7, 50074–50085. [Google Scholar] [CrossRef]
  90. Verma, D.; Bivik, C.; Farahani, E.; Synnerstad, I.; Fredrikson, M.; Enerback, C.; Rosdahl, I.; Soderkvist, P. Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma. Pigment Cell Melanoma Res. 2012, 25, 506–513. [Google Scholar] [CrossRef] [Green Version]
  91. Drexler, S.K.; Bonsignore, L.; Masin, M.; Tardivel, A.; Jackstadt, R.; Hermeking, H.; Schneider, P.; Gross, O.; Tschopp, J.; Yazdi, A.S. Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc. Natl. Acad. Sci. USA 2012, 109, 18384–18389. [Google Scholar] [CrossRef] [Green Version]
  92. Fujita, K.; Ewing, C.M.; Isaacs, W.B.; Pavlovich, C.P. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int. J. Cancer 2011, 129, 424–432. [Google Scholar] [CrossRef] [Green Version]
  93. Mezzasoma, L.; Costanzi, E.; Scarpelli, P.; Talesa, V.N.; Bellezza, I. Extracellular Vesicles from Human Advanced-Stage Prostate Cancer Cells Modify the Inflammatory Response of Microenvironment-Residing Cells. Cancers 2019, 11, 1276. [Google Scholar] [CrossRef] [Green Version]
  94. Yin, X.F.; Zhang, Q.; Chen, Z.Y.; Wang, H.F.; Li, X.; Wang, H.X.; Li, H.X.; Kang, C.M.; Chu, S.; Li, K.F.; et al. NLRP3 in human glioma is correlated with increased WHO grade, and regulates cellular proliferation, apoptosis and metastasis via epithelial-mesenchymal transition and the PTEN/AKT signaling pathway. Int. J. Oncol. 2018, 53, 973–986. [Google Scholar] [CrossRef] [Green Version]
  95. Li, L.; Liu, Y. Aging-related gene signature regulated by Nlrp3 predicts glioma progression. Am. J. Cancer Res. 2015, 5, 442–449. [Google Scholar]
  96. Jia, Y.; Zhang, C.; Hua, M.; Wang, M.; Chen, P.; Ma, D. Aberrant NLRP3 inflammasome associated with aryl hydrocarbon receptor potentially contributes to the imbalance of T-helper cells in patients with acute myeloid leukemia. Oncol. Lett. 2017, 14, 7031–7044. [Google Scholar] [CrossRef] [Green Version]
  97. Hamarsheh, S.; Osswald, L.; Saller, B.S.; Unger, S.; De Feo, D.; Vinnakota, J.M.; Konantz, M.; Uhl, F.M.; Becker, H.; Lubbert, M.; et al. Oncogenic Kras(G12D) causes myeloproliferation via NLRP3 inflammasome activation. Nat. Commun. 2020, 11, 1659. [Google Scholar] [CrossRef] [Green Version]
  98. Zhao, X.; Zhang, C.; Hua, M.; Wang, R.; Zhong, C.; Yu, J.; Han, F.; He, N.; Zhao, Y.; Liu, G.; et al. NLRP3 inflammasome activation plays a carcinogenic role through effector cytokine IL-18 in lymphoma. Oncotarget 2017, 8, 108571–108583. [Google Scholar] [CrossRef] [Green Version]
  99. Rawla, P.; Sunkara, T.; Barsouk, A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz. Gastroenterol. 2019, 14, 89–103. [Google Scholar] [CrossRef]
  100. Perera, A.P.; Sajnani, K.; Dickinson, J.; Eri, R.; Korner, H. NLRP3 inflammasome in colitis and colitis-associated colorectal cancer. Mamm. Genome 2018, 29, 817–830. [Google Scholar] [CrossRef]
  101. Chassaing, B.; Aitken, J.D.; Malleshappa, M.; Vijay-Kumar, M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 2014, 104, 15.25.1–15.25.14. [Google Scholar] [CrossRef]
  102. Guo, W.; Sun, Y.; Liu, W.; Wu, X.; Guo, L.; Cai, P.; Wu, X.; Wu, X.; Shen, Y.; Shu, Y.; et al. Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer. Autophagy 2014, 10, 972–985. [Google Scholar] [CrossRef]
  103. Wang, C.; Li, P.; Xuan, J.; Zhu, C.; Liu, J.; Shan, L.; Du, Q.; Ren, Y.; Ye, J. Cholesterol Enhances Colorectal Cancer Progression via ROS Elevation and MAPK Signaling Pathway Activation. Cell. Physiol. Biochem. 2017, 42, 729–742. [Google Scholar] [CrossRef]
  104. Wang, H.; Wang, Y.; Du, Q.; Lu, P.; Fan, H.; Lu, J.; Hu, R. Inflammasome-independent NLRP3 is required for epithelial-mesenchymal transition in colon cancer cells. Exp. Cell. Res. 2016, 342, 184–192. [Google Scholar] [CrossRef]
  105. Das, S.; Shapiro, B.; Vucic, E.A.; Vogt, S.; Bar-Sagi, D. Tumor Cell-Derived IL1beta Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer. Cancer Res. 2020, 80, 1088–1101. [Google Scholar] [CrossRef] [Green Version]
  106. Brunetto, E.; De Monte, L.; Balzano, G.; Camisa, B.; Laino, V.; Riba, M.; Heltai, S.; Bianchi, M.; Bordignon, C.; Falconi, M.; et al. The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. J. Immunother. Cancer 2019, 7, 45. [Google Scholar] [CrossRef]
  107. Zhang, D.; Li, L.; Jiang, H.; Li, Q.; Wang-Gillam, A.; Yu, J.; Head, R.; Liu, J.; Ruzinova, M.B.; Lim, K.H. Tumor-Stroma IL1beta-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. Cancer Res. 2018, 78, 1700–1712. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  108. Li, X.; Liu, S.; Luo, J.; Liu, A.; Tang, S.; Liu, S.; Yu, M.; Zhang, Y. Helicobacter pylori induces IL-1beta and IL-18 production in human monocytic cell line through activation of NLRP3 inflammasome via ROS signaling pathway. Pathog. Dis. 2015, 73. [Google Scholar] [CrossRef] [PubMed]
  109. Semper, R.P.; Mejias-Luque, R.; Gross, C.; Anderl, F.; Muller, A.; Vieth, M.; Busch, D.H.; Prazeres da Costa, C.; Ruland, J.; Gross, O.; et al. Helicobacter pylori-induced IL-1beta secretion in innate immune cells is regulated by the NLRP3 inflammasome and requires the cag pathogenicity island. J. Immunol. 2014, 193, 3566–3576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  110. Kameoka, S.; Kameyama, T.; Hayashi, T.; Sato, S.; Ohnishi, N.; Hayashi, T.; Murata-Kamiya, N.; Higashi, H.; Hatakeyama, M.; Takaoka, A. Helicobacter pylori induces IL-1beta protein through the inflammasome activation in differentiated macrophagic cells. Biomed. Res. 2016, 37, 21–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  111. Perez-Figueroa, E.; Torres, J.; Sanchez-Zauco, N.; Contreras-Ramos, A.; Alvarez-Arellano, L.; Maldonado-Bernal, C. Activation of NLRP3 inflammasome in human neutrophils by Helicobacter pylori infection. Innate Immun. 2016, 22, 103–112. [Google Scholar] [CrossRef] [Green Version]
  112. Ng, G.Z.; Menheniott, T.R.; Every, A.L.; Stent, A.; Judd, L.M.; Chionh, Y.T.; Dhar, P.; Komen, J.C.; Giraud, A.S.; Wang, T.C.; et al. The MUC1 mucin protects against Helicobacter pylori pathogenesis in mice by regulation of the NLRP3 inflammasome. Gut 2016, 65, 1087–1099. [Google Scholar] [CrossRef]
  113. Pachathundikandi, S.K.; Blaser, N.; Bruns, H.; Backert, S. Helicobacter pylori Avoids the Critical Activation of NLRP3 Inflammasome-Mediated Production of Oncogenic Mature IL-1beta in Human Immune Cells. Cancers 2020, 12, 803. [Google Scholar] [CrossRef] [Green Version]
  114. El-Omar, E.M.; Carrington, M.; Chow, W.H.; McColl, K.E.; Bream, J.H.; Young, H.A.; Herrera, J.; Lissowska, J.; Yuan, C.C.; Rothman, N.; et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404, 398–402. [Google Scholar] [CrossRef] [Green Version]
  115. Haghshenas, M.R.; Hosseini, S.V.; Mahmoudi, M.; Saberi-Firozi, M.; Farjadian, S.; Ghaderi, A. IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J. Gastroenterol. Hepatol. 2009, 24, 1119–1122. [Google Scholar] [CrossRef]
  116. Mahr, S.; Neumayer, N.; Gerhard, M.; Classen, M.; Prinz, C. IL-1beta-induced apoptosis in rat gastric enterochromaffin-like cells is mediated by iNOS, NF-kappaB, and Bax protein. Gastroenterology 2000, 118, 515–524. [Google Scholar] [CrossRef]
  117. Ying, H.Y.; Yu, B.W.; Yang, Z.; Yang, S.S.; Bo, L.H.; Shan, X.Y.; Wang, H.J.; Zhu, Y.J.; Wu, X.S. Interleukin-1B 31 C > T polymorphism combined with Helicobacter pylori-modified gastric cancer susceptibility: Evidence from 37 studies. J. Cell. Mol. Med. 2016, 20, 526–536. [Google Scholar] [CrossRef] [Green Version]
  118. Wei, Q.; Guo, P.; Mu, K.; Zhang, Y.; Zhao, W.; Huai, W.; Qiu, Y.; Li, T.; Ma, X.; Liu, Y.; et al. Estrogen suppresses hepatocellular carcinoma cells through ERbeta-mediated upregulation of the NLRP3 inflammasome. Lab. Invest. 2015, 95, 804–816. [Google Scholar] [CrossRef]
  119. Shi, C.; Yang, H.; Zhang, Z. Involvement of Nucleotide-Binding Oligomerization Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome in the Pathogenesis of Liver Diseases. Front. Cell Dev. Biol. 2020, 8, 139. [Google Scholar] [CrossRef] [Green Version]
  120. Wei, Q.; Zhu, R.; Zhu, J.; Zhao, R.; Li, M. E2-Induced Activation of the NLRP3 Inflammasome Triggers Pyroptosis and Inhibits Autophagy in HCC Cells. Oncol. Res. 2019, 27, 827–834. [Google Scholar] [CrossRef]
  121. Fan, S.H.; Wang, Y.Y.; Lu, J.; Zheng, Y.L.; Wu, D.M.; Li, M.Q.; Hu, B.; Zhang, Z.F.; Cheng, W.; Shan, Q. Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome. PLoS ONE 2014, 9, e89961. [Google Scholar] [CrossRef] [PubMed]
  122. Wan, L.; Yuan, X.; Liu, M.; Xue, B. miRNA-223-3p regulates NLRP3 to promote apoptosis and inhibit proliferation of hep3B cells. Exp. Ther. Med. 2018, 15, 2429–2435. [Google Scholar] [CrossRef] [PubMed]
  123. Saber, S.; Ghanim, A.M.H.; El-Ahwany, E.; El-Kader, E.M.A. Novel complementary antitumour effects of celastrol and metformin by targeting IkappaBkappaB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis. Cancer Chemother. Pharmacol. 2020, 85, 331–343. [Google Scholar] [CrossRef]
  124. Li, P.; Liu, Y.; He, Q. Anisodamine Suppressed the Growth of Hepatocellular Carcinoma Cells, Induced Apoptosis and Regulated the Levels of Inflammatory Factors by Inhibiting NLRP3 Inflammasome Activation. Drug Des. Devel. Ther. 2020, 14, 1609–1620. [Google Scholar] [CrossRef]
  125. Brocker, C.N.; Kim, D.; Melia, T.; Karri, K.; Velenosi, T.J.; Takahashi, S.; Aibara, D.; Bonzo, J.A.; Levi, M.; Waxman, D.J.; et al. Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting. Nat. Commun. 2020, 11, 5847. [Google Scholar] [CrossRef]
  126. Amant, F.; Mirza, M.R.; Koskas, M.; Creutzberg, C.L. Cancer of the corpus uteri. Int. J. Gynaecol. Obstet. 2018, 143 (Suppl. S2), 37–50. [Google Scholar] [CrossRef] [Green Version]
  127. Bhatla, N.; Aoki, D.; Sharma, D.N.; Sankaranarayanan, R. Cancer of the cervix uteri. Int. J. Gynaecol. Obstet. 2018, 143 (Suppl. S2), 22–36. [Google Scholar] [CrossRef]
  128. De Castro-Sobrinho, J.M.; Rabelo-Santos, S.H.; Fugueiredo-Alves, R.R.; Derchain, S.; Sarian, L.O.; Pitta, D.R.; Campos, E.A.; Zeferino, L.C. Bacterial vaginosis and inflammatory response showed association with severity of cervical neoplasia in HPV-positive women. Diagn. Cytopathol. 2016, 44, 80–86. [Google Scholar] [CrossRef]
  129. Kriek, J.M.; Jaumdally, S.Z.; Masson, L.; Little, F.; Mbulawa, Z.; Gumbi, P.P.; Barnabas, S.L.; Moodley, J.; Denny, L.; Coetzee, D.; et al. Female genital tract inflammation, HIV co-infection and persistent mucosal Human Papillomavirus (HPV) infections. Virology 2016, 493, 247–254. [Google Scholar] [CrossRef]
  130. He, A.; Shao, J.; Zhang, Y.; Lu, H.; Wu, Z.; Xu, Y. CD200Fc reduces LPS-induced IL-1beta activation in human cervical cancer cells by modulating TLR4-NF-kappaB and NLRP3 inflammasome pathway. Oncotarget 2017, 8, 33214–33224. [Google Scholar] [CrossRef] [Green Version]
  131. Berek, J.S.; Kehoe, S.T.; Kumar, L.; Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet. 2018, 143 (Suppl. S2), 59–78. [Google Scholar] [CrossRef]
  132. Luborsky, J.; Barua, A.; Edassery, S.; Bahr, J.M.; Edassery, S.L. Inflammasome expression is higher in ovarian tumors than in normal ovary. PLoS ONE 2020, 15, e0227081. [Google Scholar] [CrossRef]
  133. Wu, H.; Liu, J.; Zhang, Y.; Li, Q.; Wang, Q.; Gu, Z. miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway. Clin. Transl. Oncol. 2021, 23, 257–264. [Google Scholar] [CrossRef]
  134. Zappa, C.; Mousa, S.A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung. Cancer Res. 2016, 5, 288–300. [Google Scholar] [CrossRef] [Green Version]
  135. O’Callaghan, D.S.; O’Donnell, D.; O’Connell, F.; O’Byrne, K.J. The role of inflammation in the pathogenesis of non-small cell lung cancer. J. Thorac. Oncol. 2010, 5, 2024–2036. [Google Scholar] [CrossRef] [Green Version]
  136. Chen, L.; Lan, Z. Polydatin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation by inhibiting NF-kappaB/NLRP3 inflammasome activation via the AMPK/SIRT1 pathway. Food Funct. 2017, 8, 1785–1792. [Google Scholar] [CrossRef]
  137. Zou, J.; Yang, Y.; Yang, Y.; Liu, X. Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-kappaB pathway. Biomed. Pharmacother. 2018, 108, 130–136. [Google Scholar] [CrossRef]
  138. Carmi, Y.; Rinott, G.; Dotan, S.; Elkabets, M.; Rider, P.; Voronov, E.; Apte, R.N. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J. Immunol. 2011, 186, 3462–3471. [Google Scholar] [CrossRef] [Green Version]
  139. Tang, D.; Liu, H.; Zhao, Y.; Qian, D.; Luo, S.; Patz, E.F., Jr.; Su, L.; Shen, S.; Christian, I.D.; Gao, W.; et al. Genetic variants of BIRC3 and NRG1 in the NLRP3 inflammasome pathway are associated with non-small cell lung cancer survival. Am. J. Cancer Res. 2020, 10, 2582–2595. [Google Scholar]
  140. Coughlin, S.S. Epidemiology of Breast Cancer in Women. Adv. Exp. Med. Biol. 2019, 1152, 9–29. [Google Scholar] [CrossRef] [PubMed]
  141. Segovia-Mendoza, M.; Morales-Montor, J. Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology. Front. Immunol. 2019, 10, 348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  142. Soysal, S.D.; Tzankov, A.; Muenst, S.E. Role of the Tumor Microenvironment in Breast Cancer. Pathobiology 2015, 82, 142–152. [Google Scholar] [CrossRef] [PubMed]
  143. Liu, T.; Zhou, L.; Li, D.; Andl, T.; Zhang, Y. Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment. Front. Cell Dev. Biol. 2019, 7, 60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  144. Ershaid, N.; Sharon, Y.; Doron, H.; Raz, Y.; Shani, O.; Cohen, N.; Monteran, L.; Leider-Trejo, L.; Ben-Shmuel, A.; Yassin, M.; et al. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis. Nat. Commun. 2019, 10, 4375. [Google Scholar] [CrossRef] [Green Version]
  145. Apte, R.N.; Krelin, Y.; Song, X.; Dotan, S.; Recih, E.; Elkabets, M.; Carmi, Y.; Dvorkin, T.; White, R.M.; Gayvoronsky, L.; et al. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur. J. Cancer 2006, 42, 751–759. [Google Scholar] [CrossRef]
  146. Baker, K.J.; Houston, A.; Brint, E. IL-1 Family Members in Cancer; Two Sides to Every Story. Front. Immunol. 2019, 10, 1197. [Google Scholar] [CrossRef] [Green Version]
  147. Reed, J.R.; Leon, R.P.; Hall, M.K.; Schwertfeger, K.L. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res. 2009, 11, R21. [Google Scholar] [CrossRef] [Green Version]
  148. Feng, X.; Luo, Q.; Zhang, H.; Wang, H.; Chen, W.; Meng, G.; Chen, F. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma. J. Exp. Clin. Cancer Res. 2017, 36, 81. [Google Scholar] [CrossRef] [Green Version]
  149. Feng, X.; Luo, Q.; Wang, H.; Zhang, H.; Chen, F. MicroRNA-22 suppresses cell proliferation, migration and invasion in oral squamous cell carcinoma by targeting NLRP3. J. Cell. Physiol. 2018, 233, 6705–6713. [Google Scholar] [CrossRef]
  150. Ju, M.; Bi, J.; Wei, Q.; Jiang, L.; Guan, Q.; Zhang, M.; Song, X.; Chen, T.; Fan, J.; Li, X.; et al. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Brief. Bioinform. 2020. [Google Scholar] [CrossRef]
  151. Karki, R.; Kanneganti, T.D. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat. Rev. Cancer 2019, 19, 197–214. [Google Scholar] [CrossRef]
  152. Lee, H.E.; Lee, J.Y.; Yang, G.; Kang, H.C.; Cho, Y.Y.; Lee, H.S.; Lee, J.Y. Inhibition of NLRP3 inflammasome in tumor microenvironment leads to suppression of metastatic potential of cancer cells. Sci. Rep. 2019, 9, 12277. [Google Scholar] [CrossRef] [Green Version]
  153. Okamoto, M.; Liu, W.; Luo, Y.; Tanaka, A.; Cai, X.; Norris, D.A.; Dinarello, C.A.; Fujita, M. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J. Biol. Chem. 2010, 285, 6477–6488. [Google Scholar] [CrossRef] [Green Version]
  154. Wang, M.; Zhao, J.; Zhang, L.; Wei, F.; Lian, Y.; Wu, Y.; Gong, Z.; Zhang, S.; Zhou, J.; Cao, K.; et al. Role of tumor microenvironment in tumorigenesis. J. Cancer 2017, 8, 761–773. [Google Scholar] [CrossRef]
  155. Karan, D.; Dubey, S. From Inflammation to Prostate Cancer: The Role of Inflammasomes. Adv. Urol. 2016, 2016, 3140372. [Google Scholar] [CrossRef] [Green Version]
  156. Veeranki, S. Role of inflammasomes and their regulators in prostate cancer initiation, progression and metastasis. Cell. Mol. Biol. Lett. 2013, 18, 355–367. [Google Scholar] [CrossRef] [Green Version]
  157. Vlaeminck-Guillem, V. Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management. Front. Oncol. 2018, 8, 222. [Google Scholar] [CrossRef]
  158. Karan, D.; Tawfik, O.; Dubey, S. Expression analysis of inflammasome sensors and implication of NLRP12 inflammasome in prostate cancer. Sci. Rep. 2017, 7, 4378. [Google Scholar] [CrossRef]
  159. Moossavi, M.; Parsamanesh, N.; Bahrami, A.; Atkin, S.L.; Sahebkar, A. Role of the NLRP3 inflammasome in cancer. Mol. Cancer 2018, 17, 158. [Google Scholar] [CrossRef] [Green Version]
  160. Xue, L.; Lu, B.; Gao, B.; Shi, Y.; Xu, J.; Yang, R.; Xu, B.; Ding, P. NLRP3 Promotes Glioma Cell Proliferation and Invasion via the Interleukin-1beta/NF-kappaB p65 Signals. Oncol. Res. 2019, 27, 557–564. [Google Scholar] [CrossRef]
  161. Shang, S.; Wang, L.; Zhang, Y.; Lu, H.; Lu, X. The Beta-Hydroxybutyrate Suppresses the Migration of Glioma Cells by Inhibition of NLRP3 Inflammasome. Cell. Mol. Neurobiol. 2018, 38, 1479–1489. [Google Scholar] [CrossRef] [PubMed]
  162. Coll, R.C.; Robertson, A.A.; Chae, J.J.; Higgins, S.C.; Munoz-Planillo, R.; Inserra, M.C.; Vetter, I.; Dungan, L.S.; Monks, B.G.; Stutz, A.; et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 2015, 21, 248–255. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  163. Coll, R.C.; Hill, J.R.; Day, C.J.; Zamoshnikova, A.; Boucher, D.; Massey, N.L.; Chitty, J.L.; Fraser, J.A.; Jennings, M.P.; Robertson, A.A.B.; et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat. Chem. Biol. 2019, 15, 556–559. [Google Scholar] [CrossRef] [PubMed]
  164. Tapia-Abellan, A.; Angosto-Bazarra, D.; Martinez-Banaclocha, H.; de Torre-Minguela, C.; Ceron-Carrasco, J.P.; Perez-Sanchez, H.; Arostegui, J.I.; Pelegrin, P. MCC950 closes the active conformation of NLRP3 to an inactive state. Nat. Chem. Biol. 2019, 15, 560–564. [Google Scholar] [CrossRef]
  165. Yaw, A.C.K.; Chan, E.W.L.; Yap, J.K.Y.; Mai, C.W. The effects of NLRP3 inflammasome inhibition by MCC950 on LPS-induced pancreatic adenocarcinoma inflammation. J. Cancer Res. Clin. Oncol. 2020, 146, 2219–2229. [Google Scholar] [CrossRef]
  166. Perera, A.P.; Fernando, R.; Shinde, T.; Gundamaraju, R.; Southam, B.; Sohal, S.S.; Robertson, A.A.B.; Schroder, K.; Kunde, D.; Eri, R. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci. Rep. 2018, 8, 8618. [Google Scholar] [CrossRef] [Green Version]
  167. Dai, Z.; Chen, X.Y.; An, L.Y.; Li, C.C.; Zhao, N.; Yang, F.; You, S.T.; Hou, C.Z.; Li, K.; Jiang, C.; et al. Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis. J. Med. Chem. 2021, 64, 871–889. [Google Scholar] [CrossRef]
  168. Liu, W.; Guo, W.; Wu, J.; Luo, Q.; Tao, F.; Gu, Y.; Shen, Y.; Li, J.; Tan, R.; Xu, Q.; et al. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem. Pharmacol. 2013, 85, 1504–1512. [Google Scholar] [CrossRef]
  169. Zhao, Y.; Guo, Q.; Zhu, Q.; Tan, R.; Bai, D.; Bu, X.; Lin, B.; Zhao, K.; Pan, C.; Chen, H.; et al. Flavonoid VI-16 protects against DSS-induced colitis by inhibiting Txnip-dependent NLRP3 inflammasome activation in macrophages via reducing oxidative stress. Mucosal Immunol. 2019, 12, 1150–1163. [Google Scholar] [CrossRef] [Green Version]
  170. Wu, X.F.; Ouyang, Z.J.; Feng, L.L.; Chen, G.; Guo, W.J.; Shen, Y.; Wu, X.D.; Sun, Y.; Xu, Q. Suppression of NF-kappaB signaling and NLRP3 inflammasome activation in macrophages is responsible for the amelioration of experimental murine colitis by the natural compound fraxinellone. Toxicol. Appl. Pharmacol. 2014, 281, 146–156. [Google Scholar] [CrossRef]
  171. He, X.; Wei, Z.; Wang, J.; Kou, J.; Liu, W.; Fu, Y.; Yang, Z. Alpinetin attenuates inflammatory responses by suppressing TLR4 and NLRP3 signaling pathways in DSS-induced acute colitis. Sci. Rep. 2016, 6, 28370. [Google Scholar] [CrossRef]
  172. Hughes, M.M.; Hooftman, A.; Angiari, S.; Tummala, P.; Zaslona, Z.; Runtsch, M.C.; McGettrick, A.F.; Sutton, C.E.; Diskin, C.; Rooke, M.; et al. Glutathione Transferase Omega-1 Regulates NLRP3 Inflammasome Activation through NEK7 Deglutathionylation. Cell Rep. 2019, 29, 151–161 e155. [Google Scholar] [CrossRef] [Green Version]
  173. Tummala, P.; Rooke, M.; Dahlstrom, J.E.; Takahashi, S.; Casarotto, M.G.; Fernando, N.; Hughes, M.M.; O’Neill, L.A.J.; Board, P.G. Glutathione Transferase Omega 1 confers protection against azoxymethane-induced colorectal tumour formation. Carcinogenesis 2021. [Google Scholar] [CrossRef]
  174. Jung, H.W.; Chung, Y.S.; Kim, Y.S.; Park, Y.K. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp. Mol. Med. 2007, 39, 715–721. [Google Scholar] [CrossRef] [Green Version]
  175. Yu, X.; Zhao, Q.; Zhang, X.; Zhang, H.; Liu, Y.; Wu, X.; Li, M.; Li, X.; Zhang, J.; Ruan, X.; et al. Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation. Oncotarget 2017, 8, 67300–67314. [Google Scholar] [CrossRef] [Green Version]
  176. He, H.; Jiang, H.; Chen, Y.; Ye, J.; Wang, A.; Wang, C.; Liu, Q.; Liang, G.; Deng, X.; Jiang, W.; et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat. Commun. 2018, 9, 2550. [Google Scholar] [CrossRef] [Green Version]
  177. Xia, R.; Chen, S.X.; Qin, Q.; Chen, Y.; Zhang, W.W.; Zhu, R.R.; Deng, A.M. Oridonin Suppresses Proliferation of Human Ovarian Cancer Cells via Blockage of mTOR Signaling. Asian Pac. J. Cancer Prev. 2016, 17, 667–671. [Google Scholar] [CrossRef] [Green Version]
  178. Lu, Y.; Sun, Y.; Zhu, J.; Yu, L.; Jiang, X.; Zhang, J.; Dong, X.; Ma, B.; Zhang, Q. Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-gamma and inhibiting Nrf2 pathway. Cell Death Dis. 2018, 9, 15. [Google Scholar] [CrossRef] [Green Version]
  179. Xia, S.; Zhang, X.; Li, C.; Guan, H. Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi Pharm. J. 2017, 25, 638–643. [Google Scholar] [CrossRef]
  180. Song, M.; Liu, X.; Liu, K.; Zhao, R.; Huang, H.; Shi, Y.; Zhang, M.; Zhou, S.; Xie, H.; Chen, H.; et al. Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo. Mol. Cancer Ther. 2018, 17, 1540–1553. [Google Scholar] [CrossRef] [Green Version]
  181. Keller, M.; Sollberger, G.; Beer, H.D. Thalidomide inhibits activation of caspase-1. J. Immunol. 2009, 183, 5593–5599. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  182. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999, 341, 1565–1571. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  183. Dahut, W.L.; Gulley, J.L.; Arlen, P.M.; Liu, Y.; Fedenko, K.M.; Steinberg, S.M.; Wright, J.J.; Parnes, H.; Chen, C.C.; Jones, E.; et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol. 2004, 22, 2532–2539. [Google Scholar] [CrossRef] [PubMed]
  184. Jiang, H.; He, H.; Chen, Y.; Huang, W.; Cheng, J.; Ye, J.; Wang, A.; Tao, J.; Wang, C.; Liu, Q.; et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J. Exp. Med. 2017, 214, 3219–3238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  185. Zheng, Q.; Yao, D.; Cai, Y.; Zhou, T. NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1beta/Wnt/beta-catenin signaling pathway. Biosci. Rep. 2020, 40. [Google Scholar] [CrossRef] [PubMed]
  186. Liu, L.; Xu, X.; Zhang, N.; Zhang, Y.; Zhao, K. Acetylase inhibitor SI-2 is a potent anti-inflammatory agent by inhibiting NLRP3 inflammasome activation. Int. Immunopharmacol. 2020, 87, 106829. [Google Scholar] [CrossRef]
  187. Lee, W.K.; Kim, W.G.; Fozzatti, L.; Park, S.; Zhao, L.; Willingham, M.C.; Lonard, D.; O’Malley, B.W.; Cheng, S.Y. Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer. Endocr. Relat. Cancer 2020, 27, 209–220. [Google Scholar] [CrossRef]
  188. Church, L.D.; McDermott, M.F. Canakinumab: A human anti-IL-1beta monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes. Expert Rev. Clin. Immunol. 2010, 6, 831–841. [Google Scholar] [CrossRef]
  189. Ridker, P.M.; MacFadyen, J.G.; Thuren, T.; Everett, B.M.; Libby, P.; Glynn, R.J.; Group, C.T. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017, 390, 1833–1842. [Google Scholar] [CrossRef]
  190. Wong, C.C.; Baum, J.; Silvestro, A.; Beste, M.T.; Bharani-Dharan, B.; Xu, S.; Wang, Y.A.; Wang, X.; Prescott, M.F.; Krajkovich, L.; et al. Inhibition of IL1beta by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial. Cancer Res. 2020, 80, 5597–5605. [Google Scholar] [CrossRef]
  191. Dinarello, C.A. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 2010, 29, 317–329. [Google Scholar] [CrossRef] [Green Version]
  192. Hubner, M.; Effinger, D.; Wu, T.; Strauss, G.; Pogoda, K.; Kreth, F.W.; Kreth, S. The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation. Cancers 2020, 12, 433. [Google Scholar] [CrossRef] [Green Version]
  193. Holen, I.; Lefley, D.V.; Francis, S.E.; Rennicks, S.; Bradbury, S.; Coleman, R.E.; Ottewell, P. IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget 2016, 7, 75571–75584. [Google Scholar] [CrossRef] [Green Version]
  194. Isambert, N.; Hervieu, A.; Rebe, C.; Hennequin, A.; Borg, C.; Zanetta, S.; Chevriaux, A.; Richard, C.; Derangere, V.; Limagne, E.; et al. Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): A single-arm phase 2 study. Oncoimmunology 2018, 7, e1474319. [Google Scholar] [CrossRef]
Cancers 13 02297 g001 550
Figure 1. NLRP3 inflammasome priming and activation. The activation process of the NLRP3 inflammasome requires two main signals: (i) signal 1 (priming), which leads to the activation of the transcription factor NF-kappaB and the subsequent transcription of canonical and noncanonical NLRP3 inflammasome components; and (ii) signal 2 (activation), which is responsible for NLRP3 complex assembly and the subsequent release of inflammatory cytokines (IL-1β and IL-18). Priming is provided by exposure to pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) or by endogenous cytokines that activate receptors at the cell membrane. The induction of NLRP3 expression during priming is controlled by FAS-associated death domain protein (FADD) and caspase-8. NLRP3 activation is provided by a plethora of stimuli, such as PAMPs or damage-associated molecular patterns (DAMPs), ATP, and viral RNA, that in turn trigger downstream signaling events such as mitochondrial damage, mitochondrial ROS production, lysosomal disruption, and ion (K+ and Ca2+) efflux. Mitochondrial antiviral signaling protein (MAVS) mediates the NLRP3 activation induced by RNA viruses. Excessive Ca2+ released from the ER causes mitochondrial dysfunction and is implicated in NLRP3 inflammasome activation. Chloride intracellular channel protein (CLIC)-mediated Cl- efflux promotes the NEK7-NLRP3 interaction and subsequent NLRP3 inflammasome assembly. LPS can directly activate TLR4 to induce the transcription and activation of caspase-11, which in turn cleaves the pore-forming protein gasdermin D (GSDMD), which can induce pyroptosis. IL-18: interleukin-18; IL-1β: interleukin-1beta; IL-1R: interleukin 1 receptor; mt-DNA: mitochondrial DNA; ROS: reactive oxygen species; TLR: Toll-like receptor. Created with BioRender.com accessed on 30 March 2021.
Figure 1. NLRP3 inflammasome priming and activation. The activation process of the NLRP3 inflammasome requires two main signals: (i) signal 1 (priming), which leads to the activation of the transcription factor NF-kappaB and the subsequent transcription of canonical and noncanonical NLRP3 inflammasome components; and (ii) signal 2 (activation), which is responsible for NLRP3 complex assembly and the subsequent release of inflammatory cytokines (IL-1β and IL-18). Priming is provided by exposure to pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) or by endogenous cytokines that activate receptors at the cell membrane. The induction of NLRP3 expression during priming is controlled by FAS-associated death domain protein (FADD) and caspase-8. NLRP3 activation is provided by a plethora of stimuli, such as PAMPs or damage-associated molecular patterns (DAMPs), ATP, and viral RNA, that in turn trigger downstream signaling events such as mitochondrial damage, mitochondrial ROS production, lysosomal disruption, and ion (K+ and Ca2+) efflux. Mitochondrial antiviral signaling protein (MAVS) mediates the NLRP3 activation induced by RNA viruses. Excessive Ca2+ released from the ER causes mitochondrial dysfunction and is implicated in NLRP3 inflammasome activation. Chloride intracellular channel protein (CLIC)-mediated Cl- efflux promotes the NEK7-NLRP3 interaction and subsequent NLRP3 inflammasome assembly. LPS can directly activate TLR4 to induce the transcription and activation of caspase-11, which in turn cleaves the pore-forming protein gasdermin D (GSDMD), which can induce pyroptosis. IL-18: interleukin-18; IL-1β: interleukin-1beta; IL-1R: interleukin 1 receptor; mt-DNA: mitochondrial DNA; ROS: reactive oxygen species; TLR: Toll-like receptor. Created with BioRender.com accessed on 30 March 2021.
Cancers 13 02297 g001
Cancers 13 02297 g002 550
Figure 2. NLRP3 inflammasome involvement in distinct types of cancer.
Figure 2. NLRP3 inflammasome involvement in distinct types of cancer.
Cancers 13 02297 g002
Table
Table 1. Role of NLRP3 inflammasome in cancer.
Table 1. Role of NLRP3 inflammasome in cancer.
OutcomeType of CancerExperimental ModelsImpact on CancerReferences
anti tumoral roleColon cancerNlrp3-/-, Asc-/- and Caspase1-/- miceIncreased DSS-induced colitis inflammation and tumorigenesis[40,41,42,43]
Nlrp3-/- and Caspase1-/- miceIncreased oxazolone-induced colitis[44]
Nlrp3R258W mutant miceResist induced colitis and colorectal cancer[45]
Ice−/− and Nlrp3-/- miceEnhanced colorectal cancer growth[46]
Caspase1-/- miceEnhanced AOM-DSS colitis CAC model[47]
Hepatic cancerHCC and adjacent normal tissueLoss of the NLRP3 is correlated with a Higher HCC Pathological Grade[48]
Nlrp3-/-and Caspase1-/- miceHighly susceptible to CRC liver metastatic growth[46]
Lung cancercells from LC patients and controlsNLRP3 and caspase 1 levels were decreased in LC cells [49]
Breast cancerPten-/- miceNLRP3 deficiency promotes chemotherapy resistance [50]
HNSCCHNSCC cell linesCD38 triggers NLRP3 inflammasome-mediated pyroptotic cell death[51]
Chronic myeloid leukemiaCML patients and controlsLower levels of IL-1β and NLRP3 in CML patients compared to controls[52]
Multiple myelomacells from MM patients and controlsDownregulation of NLRP3 inflammasome in patients with MM compared to controls[53]
Chronic lymphocytic leukemiacells from CLL patients and controlsDownregulation of NLRP3 inflammasome in patients with CLL compared to controls[54]
pro-tumoral roleColon cancerNlrp3-/-, Asc-/- and Caspase1-/- miceProtected from DSS-colitis model[55]
CRC tissueNLRP3-positive patients had a poor prognosis.[56]
CRC and adjacent normal tissuePolymorphisms in NLRP3 are associated with poor survival[57]
macrophages surrounded CRC tissueNLRP3 activation increased migration of CRC[58]
Pancreatic cancerKC; Nlrp3-/-, Asc-/- and Caspase1-/- miceProtected from pancreatic ductal adenocarcinoma[59]
PC and adjacent normal tissueNLRP3 promotes proliferation, invasion of PC cells[60]
Nlrp3-/- miceThe platelet NLRP3 promotes platelet aggregation and tumor growth[61]
pancreatic cyst fluidhigh IL-1β levels in patients with high-grade dysplasia or cancer[62,63]
Gastric cancerGC and adjacent normal tissueEnhanced NLRP3 level correlates with GC progression[64]
GC cellsIL-1β promotes gastric cancer cell migration and invasion.[65,66,67,68,69]
Hepatic cancerHCC cellsDownregulation of NLRP3, caspase-1, IL-1β and IL-18 favor apoptosis of the HCC cell[48]
Endometrial carcinomaEndometrial cancer and adjacent normal tissueNLRP3, ASC, caspase-1, and IL-1β upregulation promote cancer progression and poor survival.[70]
Endometrial cancer and adjacent normal tissueOverexpression of NLRP3 and caspase-1 in human endometrial cancer [71]
Cervical cancercervical cancer tissue HPV+ or HPV-NLRP3 SNPs are associated to progression to cervical cancer[72]
Epithelial Ovarian CancerEOC and adjacent normal tissueEnhanced NLRP3 levels correlate with EOC progression[73,74]
Lung cancerexosomes of LC cellsNLRP3 inflammasome activation promote LC progression by IL-1β secretion [75]
human LC cell linesEnhanced IL-1β levels correlate with tumor cells proliferation and metastasis[76]
Nlrp3-/- miceNLRP3 deletion inhibits inflammation-driven mouse lung tumorigenesis[77]
Nlrp3-/- miceNLRP3 activation promotes lung metastasis[78]
LC and adjacent normal tissueEnhanced NLRP3 levels in ADC and SCLC[79]
Breast cancerhuman breast CAFsNLRP3 facilitate tumor progression and metastases[80]
BC and adjacent normal tissueNLRP3 expression in macrophages correlates with survival and metastasis [81]
BC and adjacent normal tissueNLRP3 activation promotes BC bones metastasis[82]
IL-1β-/- miceIL-1β regulates mammary tumor growth and invasiveness.[83]
Nlrp3-/-and IL-1Rα miceNLRP3 and IL-1β promote tumor growth and metastasis[84]
HNSCCHNSCC and adjacent normal tissueNLRP3 inflammasome is upregulated and associated with carcinogenesis[85,86,87]
OSCCOSCC cell lines and tissueEnhanced NLRP3, ASC and IL-1β levels correlate with tumor growth and metasases [88,89]
melanomamelanoma and adjacent normal tissueNLRP3 polymorphisms is associated with melanoma susceptibility[90]
IL-1R1-/- and Caspase-1-/-Inflammasome-dependent production of IL-1β favors tumorigenesis.[91]
Prostate cancerPca cell lines and tissueEnhanced IL-18 correlate with tumor status[92]
Pca cell linesEnhanced IL-1β correlate with tumor stage[93]
Gliomaglioma cell lines and tissueEnhanced NLRP3, ASC, caspase-1 and IL-1β levels correlate with with higher glioma grades; NLRP3 promotes glioma cell migration and invasion[94]
glioma cell linesNLRP3 inflammasome contributed to radiotherapy resistance in glioma. [95]
Acute myeloide leukemiacells from AML patients and controlsEnhanced NLRP3 levels in patients with AML [96]
KrasG12D; Nlrp3-/- mice and human leukemia cellsNLRP3 enhances myeloproliferation and cytopenia[97]
Lymphomalymphoma patients and controlPolymorphism of IL-18 (rs1946518) was significantly associated with lymphoma susceptibility [98]
Abbreviations: AML: acute myeloid leukemia; AOM: azoxymethane; BC: breast cancer; CAFs: cancer associated fibroblasts; CLL: chronic lymphocytic leukemia; CML: chronic myeloid leukemia; CRC: colorectal cancer; DSS: dextran sodium sulphate; GC: gastric cancer; HCC: hepatocellular carcinoma; HNSCC: head and neck squamous cell carcinoma; HPV: human papillomavirus; LC: lung cancer; MM: multiple myeloma; OSCC: oral cavity squamous cell carcinoma; PC: pancreatic cancer; PCa: prostate cancer.
Table
Table 2. List of compounds that impinge on NLRP3 inflammasome activation and have a potential in cancer treatment.
Table 2. List of compounds that impinge on NLRP3 inflammasome activation and have a potential in cancer treatment.
Compound NameTargetReferencesEffective Cancer TypeReferences
MCC950directly interacts with the Walker B motif within the NLRP3 NACHT domain, thereby blocking ATP hydrolysis and its active conformation[162,163,164]HNSCC[87]
PCa[165]
CML[97]
PDA[61]
DSS-induced experimental colitis in mice[166]
Compound 6directly binds the NLRP3 NACHT domain, thereby blocking ATPase activity and ASC oligomerization[167]DSS-induced experimental colitis in mice[167]
Fc11a-2targets NLRP3 inflammasome and inhibits cytokines release[168]DSS-induced experimental colitis in mice[168]
VI-16inhibits the binding of TXNIP to NLRP3 by reducing NLRP3 activation [169]DSS-induced experimental colitis in mice[169]
Polydatinsuppresses NF-kappaB signaling and NLRP3 inflammasome activation[136]NSCLC[137]
Fraxinellonesuppresses NF-kappaB signaling and NLRP3 inflammasome activation[170]DSS-induced experimental colitis in mice[170]
Alpinetininhibits NF-kappaB pathway and NLRP3 inflammasome activation[171]DSS-induced experimental colitis in mice[171]
C1-27limits NLRP3 activation by reducing ASC speck formation[172]CRC [173]
Celastrolinhibits NF-kappaB pathway, blocks ASC oligomerization and NLRP3 complex formation[174,175]DSS-induced experimental colitis in mice[175]
melanoma cancer cells[152]
Oridoninblocks NEK7-NLRP3 interaction by binding the cysteine 279 on NLRP3 NACHT domain[176]ovarian cancer[177]
osteosarcoma [178]
BC[179]
esophageal cancer[180]
Thalidomideinhibits caspase-1 activation[181]MM[182]
PCa[183]
CY-09binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity.[184]triple negative BC[185]
SI-2disrupts the interaction between NLRP3 and ASC then blocks the formation of ASC speck[186]anaplastic thyroid carcinoma[187]
Andrographolideinhibits caspase-1 activation[102]DSS-induced experimental colitis in mice[102]
CanakinumabIL-1β inhibitor[188]NSCLC[189,190]
triple negative BC, CRC, metastatic melanoma and PC-
AnakinraIL-1 receptor antagonist [191]glioblastoma [192]
AML[97]
BC[193]
CRC[194]
PDA-
MM-
Abbreviations: AML: acute myeloid leukemia; BC: breast cancer; CAFs: cancer associated fibroblasts; CML: chronic myeloid leukemia; CRC: colorectal cancer; DSS: dextran sodium sulphate; LC: lung cancer; MM: multiple myeloma; PCa: prostate cancer; PDA: pancreatic ductal adenocarcinoma.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Missiroli, S.; Perrone, M.; Boncompagni, C.; Borghi, C.; Campagnaro, A.; Marchetti, F.; Anania, G.; Greco, P.; Fiorica, F.; Pinton, P.; et al. Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer. Cancers 2021, 13, 2297. https://doi.org/10.3390/cancers13102297

AMA Style

Missiroli S, Perrone M, Boncompagni C, Borghi C, Campagnaro A, Marchetti F, Anania G, Greco P, Fiorica F, Pinton P, et al. Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer. Cancers. 2021; 13(10):2297. https://doi.org/10.3390/cancers13102297

Chicago/Turabian Style

Missiroli, Sonia, Mariasole Perrone, Caterina Boncompagni, Chiara Borghi, Alberto Campagnaro, Francesco Marchetti, Gabriele Anania, Pantaleo Greco, Francesco Fiorica, Paolo Pinton, and et al. 2021. "Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer" Cancers 13, no. 10: 2297. https://doi.org/10.3390/cancers13102297

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop